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Abstract 
Biofilm formation complicates diagnosis and treatment of bacterial 
infections. Bacterial biofilms can be defined as structurally organized 
communities of bacterial cells embedded in a matrix of extracellular 
polymeric matrix (EPS). The majority of bacteria exist as biofilms in most 
natural environments. Biofilm bacteria are highly tolerant to antimicrobials 
and host immune responses. Conventional antibiotics are inefficient in the 
treatment of biofilm-associated infections, especially those occurring in 
hospitalized patients and associated with the use of medical devices. 
Moreover, in vitro laboratory methods that have been designed for growing 
of planktonic bacteria and evaluation of antimicrobials against them are not 
applicable for biofilms. Therefore, alternative methods and models have been 
developed for investigation of biofilms and testing of antimicrobials against 
biofilm-growing bacteria. However, so far, the repertoire of existing anti-
biofilm agents is extremely limited and thus, there is a great need for the 
discovery and development of novel anti-biofilm compounds. In that context, 
the primary aim of this thesis project was to identify biofilm inhibitors from 
naturally-inspired sources. Towards this goal, 3570 compounds were 
screened for biofilm inhibition.  
Screening campaigns were designed to explore different strategies aimed 
at the discovery of anti-biofilm leads with bactericidal or non-bactericidal 
effects. In one direction, two synthetic flavan derivatives as well as the D-
tryptophan and the β-cyclohexyl-L-alanine derivatives of (+)-dehydroabietic 
acid (DHA) were identified as anti-biofilm leads. These leads were 
characterized as desirable antimicrobials that displayed both antibacterial and 
anti-biofilm activity in contrast to conventional antibiotics. They were able to 
prevent biofilm formation and eradicate pre-formed biofilms at micromolar 
concentrations. A second discovery strategy allowed the identification of two 
flavone derivatives as Quorum Sensing Inhibitors (QSIs). As opposed to the 
leads identified by the first strategy, these leads did not display any 
bactericidal activity but interfered with biofilm formation and maturation. 
Furthermore, given the relevance of biofilm models for drug discovery, a 
comparative methodological study was also performed. Efficacy testing of 
conventional antibiotics in prevention of biofilm formation was conducted in 
two distinct biofilm models, microtiter well plates (MWP) and drip flow 
reactor (DFR), classified as closed and open systems, respectively. The goal 
was to investigate if the choice of model affects the experimental outcome. 
The comparative study revealed that biofilms grown under continuous flow 
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of nutrients displayed significantly higher antimicrobial tolerance than those 
grown in the absence of flow.  
Altogether, this thesis project led to the identification of anti-biofilm leads, 
which can serve as starting points for further optimization towards more 
potent biofilm inhibitors that can be used either as alternatives to 
conventional antibiotics or as adjunctive agents in combination with 
conventional antibiotics or other antimicrobials. Given the complexity of 
biofilms, it is increasingly understood that no single strategy will be sufficient 
for biofilm control. Thus, complementary strategies aimed at interfering with 
biofilms in different mechanisms could offer a promising solution. Further, 
when selecting the best anti-biofilm compounds, activity of the most 
promising compounds needs to be confirmed using different biofilm models, 
as the choice of biofilm model was shown to have a profound impact on the 
experimental outcome.  
ix 
 
Svensk sammanfattning 
Att bakterier bildar biofilmer komplicerar diagnos och behandling av 
bakteriella infektioner. Bakteriella biofilmer kan definieras som komplexa 
bakteriesamhällen inbäddade i en matris av extracellulära polymera 
substanser (EPS), som består av polysackarider, proteiner och extracellulärt 
DNA. De facto är biofilmer den dominerande livsformen av bakterier i 
naturen. Bakterier kan fästa vid och bilda biofilmer på en mängd olika ytor, 
t.ex. på tänderna i form av plack, i vävnader, på proteser och även på 
fartygsskrov och stenar. Matrisen skyddar bakterierna från antibiotika, 
desinfektionsmedel och kroppens immunförsvar. Dessutom skiljer sig 
biofilmbakterierna markant från de bakterier som existerar som planktoniska, 
enstaka celler och växer i flytande medier, särskilt med avseende på tillväxt, 
stresstålighet och genuttryck. Detta ytterligare ökar deras motståndskraft och 
leder till uppkomsten av kroniska och svårbehandlade infektioner. 
Biofilmsalstrande bakterier står för upp till 80 procent av alla bakteriella 
infektioner, speciellt dem associerade med användningen av främmande 
material, t.ex. i form av katetrar och implantat, och hos hospitaliserade 
patienter. Trots detta riktar antibiotika in sig på att döda endast planktoniska 
bakterier. Hittills har inget antibiotikum speciellt mot bakteriella biofilmer 
godkänts av myndigheter. 
Naturprodukter har varit en viktig källa i läkemedelsutvecklingen, 
speciellt i samband av upptäckten av antibiotika. I detta sammanhang var 
syftet med denna avhandling att identifiera bioaktiva substanser mot 
bakteriella biofilmer från substansbibliotek, innehållande föreningar som 
antingen är naturprodukter eller syntetiserade derivat, som alternativ till 
konventionell antibiotika. För detta ändamål utnyttjades olika 
sållningsmetoder vid sållningen av sammanlagt 3 570 substanser. Därtill 
utfördes en jämförande studie med antibiotika i två olika experimentella 
system som används för biofilmstudier för att undersöka inverkan av 
systemet på experimentella resultat. 
Under projektets gång identifierades och karaktäriserades ett antal 
naturinspirerade substanser med olika verkningsmekanismer. Två syntetiska 
flavanderivat från ett stort substansbibliotek med flavonoider och D-
tryptofan och β-cyklohexyl-L-alaninderivat av dihydroabietinsyra 
identifierades som ledtrådsmolekyler med hjälp av fenotypisk sållning. Till 
skillnad från antibiotika, uppvisade dessa molekyler antimikrobiell effekt 
både på biofilmbakterier och planktoniska celler. Målbaserad sållning av ett 
substansbibliotek med 3 040 naturproduktderivat ledde till identifikation av 
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substanser som inhiberade biofilmbildning genom att hämma bakteriell 
kommunikation, quorum sensing-signalering. Två derivat av flavonklass 
karaktäriserades som mest aktiva. Dessa substanser uppvisade 
biofilmreducerande effekt utan att bakterieväxten påverkades. Slutligen 
påvisade den jämförande studien att valet av experimentellt system påverkar 
antibiotikakänsligheten hos biofilmer. Biofilmer som hade växt i ett 
flödessystem, droppflödesreaktor (eng. drip flow reactor), var betydligt 
motståndskraftigare mot antibiotika än de som växte i mikrotiterplattor. 
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1 Introduction 
Bacteria can switch between two lifestyles, and exist as free-floating, 
planktonic cells or as surface-associated communities encased in a matrix of 
extracellular polymeric substances, also known as biofilms. In fact, up to 99% 
of all bacteria are found in the form of biofilm at various stages of growth 
(Davey and O’Toole 2000). Biofilm bacteria exhibit distinct phenotype from 
planktonic counterparts, particularly with respect to gene expression and 
growth rate, and are significantly more tolerant to antimicrobials and host 
immune responses (Stewart and Franklin 2008). Several features connected to 
the biofilm mode of growth contribute to the tolerance of biofilms. First, 
biofilm matrix protects cells from external insults and environmental stresses. 
Secondly, within the biofilm, bacteria exist as a heterogeneous population of 
cells that are in various physiological states due to oxygen and nutrient 
gradients. Further, the non-dividing, dormant population of bacteria, 
persister cells, is in well-protected mode and highly tolerant antibiotics. 
Consequently, cells embedded in a biofilm are typically up to 1000 times more 
tolerant to antimicrobials than the planktonic cells of the same species (Olson 
et al. 2002). 
Biofilms have a significant impact on human health, as it has been 
estimated that up to 80% of all human bacterial infections can be attributed to 
biofilm formation (Bjarnsholt 2013). Acute infections are generally curable 
with conventional antibiotics. However, when an infection develops into 
chronic state involving a biofilm, it may be impossible to eradicate. Despite 
this, antimicrobial drug discovery has conventionally focused on planktonic 
bacteria. Until now, all the marketed antibiotics are targeting the growth of 
dividing, planktonic cells (Fey 2010), and thereby, fail in the treatment of 
biofilm-associated infections. Since biofilms differ from planktonic cells by 
phenotype and morphology, several biofilm models have been developed for 
growing biofilms and evaluating antimicrobials against them (Lebeaux et al. 
2013). However, to date, no antimicrobial agent has been approved by the 
regulatory authorities to be specifically used against biofilm-growing 
bacteria. Thus, novel anti-biofilm agents and approaches to treat and prevent 
biofilm formation are in great demand. 
The majority of all marketed antimicrobials are based on natural 
compounds or synthetic derivatives of natural compounds (Newman and 
Cragg 2016). Therefore, natural compounds that have coevolved with bacteria 
in nature provide a reasonable starting point for exploration of anti-biofilm 
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compounds. As the eradication of existing biofilms is challenging, prevention 
of biofilm formation is an attractive approach to biofilm control. Further, since 
conventional antibiotics are ineffective against pre-formed biofilms, 
compounds that can eradicate pre-formed biofilms are of great importance. In 
this thesis, the search for compounds that act as efficient biofilm inhibitors 
was performed.  
However, it has been argued that bactericidal compounds, while effective 
in the short-term, are also prone to the development of resistance. Therefore, 
searching for compounds that interfere with the biofilm lifecycle without 
bactericidal activity, for example via inhibition of quorum sensing (QS), is 
increasingly regarded as a valuable therapeutic alternative (Brackman and 
Coenye 2015). This strategy was also explored in this thesis project.  
Finally, there is significant evidence suggesting that the choice of the 
biofilm model can have a significant impact on the experimental outcome 
(Buckingham-Meyer, Goeres and Hamilton 2007, Coenye and Nelis 2010). 
Understanding the differences between biofilm models is an essential aspect 
of biofilm research, and it greatly impacts drug discovery strategies. Thus, the 
evaluation of antimicrobials against biofilms in various models was also a 
focus in this thesis project.
Literature review 
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2 Literature review 
2.1 Bacterial biofilms 
Bacterial biofilms are defined as surface-associated, organized 
communities of bacterial cells embedded in a self-produced matrix of 
extracellular polymeric substances (EPS) (Donlan 2002). The biofilm 
phenomenon was first described in the 17th century by Antonie van 
Leeuwenhoek, who discovered bacteria in the form of plaque from his teeth 
and, using a microscope, observed that the “animalculi” had produced a 
community (Costerton, Stewart and Greenberg 1999). Today, it is well 
recognized that bacteria exist predominantly as biofilms rather than as free-
floating cells in most environments (Watnick and Kolter 2000, Flemming et al. 
2016). The biofilm mode of growth enables bacteria to resist environmental 
stresses; it protects bacteria from desiccation and external insults, including 
antimicrobials, host defenses and predators (Dunne 2002, López, Vlamakis 
and Kolter 2010).	 Biofilms can be formed virtually everywhere and have 
important consequences, as they can provide both beneficial and detrimental 
effects (Kolter and Losick 1998).  Examples of beneficial biofilms include those 
in natural ecosystems, such as in streams, soil and plant rhizosphere allowing 
mutualistic symbioses, and commensal biofilms in the human body (Battin et 
al. 2016, Burmølle et al. 2010). However, in medical and industrial settings 
biofilms cause severe problems, i.e. chronic and persistent infections as well 
as biofouling and corrosion (Bjarnsholt 2013, Dobretsov, Abed and Teplitski 
2013). This latter aspect has established biofilm control strategies as an 
attractive and important research area.  
2.1.1 Biofilm lifecycle  
The switch between planktonic and biofilm mode of growth occurs in 
response to environmental changes. This transition involves a number of 
physical, chemical and biological regulatory mechanisms and components 
that greatly differ between bacterial species, and even among strains of the 
same species (O’Toole, Kaplan and Kolter 2000, López et al. 2010). The best 
characterized molecular mechanism beyond biofilm formation is extracellular 
quorum sensing (QS), which coordinates expression of biofilm-specific genes 
in a cell density-dependent manner (Rutherford and Bassler 2012).  
Biofilm formation is strongly influenced by the environmental conditions 
(Tolker-Nielsen and Molin 2000). For example, in the case of Pseudomonas 
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aeruginosa, environments rich in nutrients promote biofilm formation, 
whereas nutrient depletion leads to dispersal (Delaquis et al. 1989, Hunt et al. 
2004). Contrary to P. aeruginosa, biofilm formation of Escherichia coli and 
Staphylococcus aureus is enhanced in the absence of nutrients (Ryu, Kim and 
Beuchat 2004, Pagedar, Singh and Batish 2010). Despite differences in 
regulatory components and molecular mechanisms, bacterial biofilm 
formation in general involves three consecutive steps; attachment, maturation 
and dispersal, and requires three essential components; bacteria, matrix and 
surface (Joo and Otto 2012). Biofilm formation is schematically shown in 
Figure 1.  
 
 
 
Figure 1. The biofilm lifecycle. The transition between the growth modes is a dynamic 
process. 
 
Several studies have shown that the initial attachment of bacteria to the 
surfaces typically occurs within minutes, and depending on the species and 
environmental conditions, microcolonies are formed within one to four hours 
after the irreversible attachment (Fallarero et al. 2013, Costerton 1984). 
Bacteria start to produce EPS within 6-12 hours and reach the highest cell 
density within 48 to 96 hours (Shafique et al. 2017, Anwar, Strap and 
Costerton 1992). 
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2.1.1.1 Attachment  
Biofilm formation is initiated by dynamic surface attachment of planktonic 
bacteria. The attachment involves two steps, initial reversible attachment and 
irreversible attachment. Physical forces, including van der Waals forces, steric 
and electrostatic interactions along with extracellular bacterial surface 
structures, such as flagella and cell wall-attached adhesins, are involved in the 
initial adhesion step, while the expression of cell adhesion structures, such as 
pili and fimbriae, has been associated with the irreversibly binding (Pratt and 
Kolter 1998, Hall-Stoodley and Stoodley 2002). For instance, staphylococcal 
adherence to host tissues is mediated by specific adhesins, the microbial 
surface components recognizing adhesive matrix molecules (MSCRAMMs) 
(Heilmann 2011, Paharik and Horswill 2016), and also to abiotic surfaces 
when covered with the host plasma components (Cucarella et al. 2001). Also, 
autolysins (Heilmann et al. 1997), and the biofilm-associated protein (Bap), 
which is present in S. aureus isolates from animals with bovine mastitis but 
not in human isolates (Tormo et al. 2005), are involved in the adherence and 
biofilm formation of staphylococci. Furthermore, the polysaccharide 
intercellular adhesin (PIA) plays an important role (Arciola et al. 2015). In 
turn, flagella and type IV pili are essential factors mediating the initial 
attachment of P. aeruginosa and E. coli (Laverty, Gorman and Gilmore 2014).  
2.1.1.2 Maturation  
After the reversible attachment, bacterial cells start to communicate with 
each other by means of chemical signals (autoinducers), which result in the 
expression of biofilm-specific genes and the initiation of the biofilm 
maturation process (Davies et al. 1998). This stage involves aggregation of the 
cells into microcolonies and subsequent production of EPS followed by the 
growth and maturation of the adhered cells (Hall-Stoodley, Costerton and 
Stoodley 2004). Microcolonies are separated by water channels that enable the 
supply of nutrients and oxygen throughout the biofilm, as well as the draining 
of metabolic end products, respectively (Davey and O’Toole 2000, Lindsay 
and von Holy 2006). However, nutrients and oxygen are unevenly distributed 
within the biofilm, and pH and cell density vary as well. In response to the 
environmental conditions, cells differentiate and constitute a heterogeneous 
population within the biofilm (Stewart and Franklin 2008, Stoodley et al. 
2002). The composition of biofilm matrix varies between species, but 
generally, the EPS is composed of proteins, polysaccharides and extracellular 
DNA (eDNA). For instance, three polysaccharides, Pel, Psl and alginate, have 
been shown to have an important role in biofilm formation and maintenance 
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of P. aeruginosa (Colvin et al. 2012). Poly-N-acetyl glucosamine (PNAG), in 
turn, is a major polysaccharide in the matrix of Staphylococcus spp. biofilms 
(Kropec et al. 2005). Importantly, the matrix acts as a stabilizing scaffold for 
the biofilm structure (Flemming and Wingender 2010). 
2.1.1.3 Dispersal 
The last stage, dispersal, involves the detachment of bacteria from outer 
layers of the biofilm and the colonization of new surfaces by the detached 
cells. The dispersal of cells also leads to dissemination of infections (Parsek 
and Singh 2003). Generally, it has been well recognized that cells switch to the 
planktonic mode and regain the susceptibility when they disperse from the 
biofilm (Singh et al. 2009, Kaplan 2010). However, recently a third phenotype 
of bacteria, namely dispersed cells, has been identified (McDougald et al. 
2011). Dispersed cells with distinct physiology from the planktonic and 
biofilm cells have been characterized as highly motile. This characteristic 
allows fast colonization of new environments. Notably, dispersed cells of P. 
aeruginosa have been shown to be more virulent against macrophages 
compared to conventionally grown planktonic cells (Chua et al. 2014).  
Dispersal can occur in two distinct ways, passively or actively. The passive 
detachment of cells, which occurs as a result of external influences, such as 
mechanical interruption or fluid shear, can be categorized into two sub-types, 
sloughing and erosion. Sloughing refers to rapid, massive loss of biofilm, 
while erosion happens continuously, leading to the detachment of single cells 
or small portions of the biofilm (Stoodley et al. 2001, Kaplan 2010). In contrast 
to passive dispersal, active dispersal refers to the events induced by the 
bacteria in response to a variety of environmental changes, including 
alteration in nutrient availability (Hunt et al. 2004), oxygen depletion 
(Thormann et al. 2005), toxic byproducts, bacteriophages and changes in 
temperature (Fleming and Rumbaugh 2017). In addition, production of EPS 
degrading enzymes can contribute to bacterial detachment of both gram-
negative and gram-positive species (Hall-Stoodley and Stoodley 2005), as well 
as presence of fatty acids (Davies and Marques 2009), and QS-molecules 
(Boles and Horswill 2008, Lauderdale et al. 2010, Richards et al. 2008). 
2.1.1.4 Quorum sensing (QS) 
QS includes production, secretion and detection of chemical signals termed 
autoinducers (AIs) (Papenfort and Bassler 2016). As the cell density increases, 
the AI concentration increases simultaneously. Once a threshold 
concentration of AI is reached, transcription of the biofilm-specific genes 
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increases. The AIs have been demonstrated to coordinate several steps of 
biofilm formation, including attachment, maturation and dispersal. 
Additionally, QS controls various features, such as bioluminescence in Vibrio 
fischeri (Miyashiro and Ruby 2012), production of virulence factors in P. 
aeruginosa (Köhler, Buckling and van Delden 2009), and antibiotic production 
in Chromobacterium violaceum (McClean et al. 1997). Importantly, most of them 
are connected to the virulent phenotype. 
Both gram-negative and gram-positive bacteria employ QS (Brackman and 
Coenye 2015). However, the QS mechanisms, as well as the signal molecules 
are diverse (Figure 2). Three main QS systems have been characterized; (i) the 
N-acyl homoserine lactone (AHL)-based system, (ii) the autoinducing peptide 
(AIP)-mediated system in gram-negative and gram-positive bacteria, 
respectively, and (iii) the autoinducer 2 (AI-2) system in both gram-negative 
and gram-positive bacteria. In gram-negative species, QS is mainly mediated 
by AHLs, which are synthesized from S-adenosylmethionine (SAM) and 
diffused through the bacterial membrane, and recognized and bound by 
cytoplasmic receptors. AHLs consist of a homoserine lactone ring bearing an 
acyl chain of C4 to C18 in length (Fuqua, Parsek and Greenberg 2001). 
Regulation of the AHL-mediated QS is coordinated by two proteins, the 
transcriptional regulator R that is homologous to LuxR in V. fischeri, and the 
autoinducer synthase I corresponding to LuxI of V. fischeri (Fuqua, Winans 
and Greenberg 1994). For example, P. aeruginosa has two pairs of LuxI/LuxR 
homologs, LasI/LasR and RhlI/RhlR (de Kievit 2009), while in C. violaceum, the 
LuxI/LuxR homolog CviI/CviR is responsible for QS (McClean et al. 1997).  
QS in gram-positive bacteria relies on secreted oligopeptides, also termed 
autoinducing peptides (AIPs), and a two-component regulatory system, 
which consists of a membrane-bound sensor and intracellular response 
regulator for controlling the gene expression (Miller and Bassler 2001). In the 
third QS system, LuxS regulates the production of AI-2 (Vendeville et al. 
2005). 
Literature review 
 
8 
 
 
Figure 2. QS in gram-negative and gram-positive bacteria. Panel A depicts 
AHL-based QS in gram-negative bacteria, and panel B AIP-mediated QS 
system in gram-positive bacteria. Adapted from Bassler (2002). 
2.1.2 Specific features of biofilms 
Biofilm mode of growth exhibits distinct phenotype from planktonic 
counterparts, particularly with respect to gene expression and protein 
production (Stewart and Franklin 2008). Bacteria within the biofilms are 
typically up to 1000-fold more tolerant to antimicrobials than their planktonic 
counterparts (Mah and O'Toole 2001, Ceri et al. 1999). Notably, development 
of antimicrobial tolerance occurs gradually over time. It has been shown that 
bacteria at early stages of biofilm development, as well as freshly formed 
biofilms, are substantially more susceptible to antibiotics than biofilms that 
have formed for 24-48 hours (Wolcott et al. 2010, Martens and Demain 2017). 
Biofilm bacteria may persist in the host due to increased evasion from host 
immune defenses, such as macrophages, which cannot penetrate the biofilm 
matrix (Moser et al. 2017). The conventional, heritable antibiotic resistance 
mechanisms include inactivation of drugs via hydrolysis (e.g., β-lactam 
resistance) (Munita, Bayer and Arias 2015) or modification of the drugs (e.g., 
aminoglycoside resistance) (Mingeot-Leclercq, Glupczynski and Tulkens 
1999), alteration of the drug targets (e.g., fluoroquinolone resistance) 
(Redgrave et al. 2014), and efflux of drugs via membrane-bound efflux pumps 
(Webber and Piddock 2003). In contrast, the antimicrobial tolerance associated 
with biofilms is a transient, non-heritable phenotype that decreases the 
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susceptibility of bacteria (Stewart and Costerton 2001). Antibiotic tolerance of 
biofilms has been attributed to multiple causes, including the failure of 
antibiotics to target biofilm embedded cells, altered microenvironments 
within the biofilms that promote activation of stress responses, slow growth 
rate and persister cells.   
The biofilm matrix provides protection from external insults and may 
represent a physical barrier to the diffusion of antibiotics, leading to retarded 
penetration (Bordi and de Bentzmann 2011). This feature, however, appears 
to be dependent on the physicochemical properties of the antimicrobials 
(Stewart 2015). For instance, rifampicin can penetrate Staphylococcus 
epidermidis biofilms (Zheng and Stewart 2002) and tetracycline E. coli biofilms 
(Stone et al. 2002), whereas transport of vancomycin through the matrix of S. 
aureus biofilms is retarded (Jefferson, Goldmann and Pier 2005). Similarly, 
hypochlorite penetration through P. aeruginosa and Klebsiella pneumoniae 
biofilms is delayed (Stewart et al. 2001). Moreover, the eDNA present in the 
matrix of P. aeruginosa biofilms has been proposed to act as a chelator of 
cationic antimicrobials, such as peptides, as well as to prevent penetration of 
aminoglycosides (Mulcahy, Charron-Mazenod and Lewenza 2008, Chiang et 
al. 2013). Additionally, enzymes, such as beta-lactamases that can degrade 
antibiotics are present in the matrix (Donné and Dewilde 2015).  For that 
reason, penetration of ampicillin through K. pneumoniae biofilm is limited 
(Anderl, Franklin and Stewart 2000).  
Nutrient and oxygen gradients within the biofilms contribute to the 
heterogeneity and differentiation of bacteria, which in turn affect the 
antimicrobial tolerance of biofilm-growing bacteria (Stewart 2002). Cells 
located at the surface are more metabolically active, while cells in the deeper 
layer of the biofilms are slow-growing due to lack of nutrients and oxygen 
suppression. As a result, cells in the different locations within a biofilm will 
respond differently to antimicrobial therapy (Nguyen et al. 2011, Poole 2012). 
Generally, antibiotics are less effective against stationary phase bacteria (Eng 
et al. 1991). For example, β-lactams target only exponentially growing bacteria 
(Tuomanen et al. 1986). Tetracycline and ciprofloxacin, in turn, have been 
reported to be effective in the killing of metabolically active cells in P. 
aeruginosa biofilms, whereas colistin was effective against the slow-growing 
fraction of the cells (Pamp et al. 2008). Further, a small fraction of the non-
dividing, dormant population termed persister cells, contribute significantly 
to the antimicrobial tolerance of biofilms (Lewis 2008). The formation of 
persisters occurs in response to bacterial stress, as well as when biofilms reach 
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the mid-exponential growth phase (Dörr, Lewis and Vulić 2009). These cells 
survive even from prolonged antibiotic treatment, thus serving as reservoirs 
of infections. When the antibiotic exposure is over, the cells start to grow again 
leading to the relapse of infection (Lewis 2007, Mulcahy et al. 2010). The 
persister cells are not exclusively associated with biofilm bacteria, but more 
prevalent among biofilms than in planktonic cultures (Spoering and Lewis 
2001). 
Notably, even though the antimicrobial tolerance of biofilms is not 
connected to the conventional resistance mechanisms, mutation frequency 
and gene transmission are increased in biofilms due to proximity of bacteria 
(Høiby et al. 2010). The biofilm mode of growth has shown to promote 
horizontal gene transfer and adaptive mutations allowing bacteria to survive 
from environmental stresses, including antibiotic treatment and starvation 
(Savage, Chopra and O'Neill 2013, Driffield et al. 2008).  
2.1.3 Clinical impact of biofilms 
Biofilms are medically important, accounting for 65-80% of all bacterial 
infections according to the US Center for Disease Control (CDC) and the 
National Institutes of Health (NIH), respectively. Biofilm formation poses a 
significant economic burden for healthcare, as it is estimated that 17 million 
biofilm infections, leading to 550,000 deaths, occur in the United States every 
year (Worthington, Richards and Melander 2012). Moreover, biofilm 
formation complicates both diagnosis and treatment of infections. Biofilm-
associated infections can occur both on host tissues, including wounds and 
lungs of cystic fibrosis patients, and on medical devices and foreign implanted 
material. Consequently, they can be divided into two groups: tissue- and 
device-related, depending on the surface involved in biofilm formation 
(Bjarnsholt 2013). Notably, the majority of nosocomial infections are biofilm-
associated and related to the use of medical devices (Percival et al. 2015). 
Typical infections associated with biofilm formation are summarized in Table 
1.  
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Table 1. Infections associated with biofilm formation and causative bacteria. 
Tissue- 
related 
infections 
Bacterial 
species 
involved 
Reference  
(ex) 
Medical 
device-related 
infections 
Bacterial 
species 
involved 
Reference 
(ex) 
Cystic fibrosis P. aeruginosa 
S. aureus 
H. influenzae 
Høiby, Ciofu and 
Bjarnsholt 2010b, 
Ahlgren et al. 2015, 
Cardines et al. 2012 
Urinary tract 
catheters 
E. coli 
K. pneumoniae 
P. aeruginosa 
Acinetobacter 
Coagulase negative 
Staphylococci (CoNS) 
Enterococci 
Niveditha et al. 
2012 
Wounds S. aureus 
P. aeruginosa 
K. pneumoniae 
E. faecalis 
Metcalf and Bowler 
2013, Gjødsbøl et 
al. 2006 
Central-
venous-
catheters 
(CVCs) 
S. aureus 
S. epidermidis 
P. aeruginosa 
K. pneumoniae 
A. baumanii 
Gahlot et al. 2014, 
Dasgupta 2002 
Chronic otitis 
media 
Staphylococci 
H. influenza 
S. pneumoniae 
M. catarrhalis 
Wessman et al. 
2015, Thornton et 
al. 2011 
Orthopedic 
implants, 
prosthetic 
joints 
S. epidermidis 
S. aureus 
Propionibacterium 
acnes 
McConoughey et 
al. 2014, 
Achermann et al. 
2014 
Urinary tract 
infection 
E.coli 
P. mirabilis 
P. aeruginosa 
K. pneumonia 
Staphylococci 
Hashemizadeh, 
Kalantar-
Neyestanaki and 
Mansouri 2017, 
Delcaru et al. 2016 
Prosthetic 
valves and 
pacemakers 
S. aureus 
CoNS 
S. pneumoniae 
P. acnes 
Cahill and 
Prendergast 2016, 
Natsheh et al. 
2014, Achermann 
et al. 2014 
Osteomyelitis Staphylococci 
Enterococci 
Streptococci 
P. aeruginosa 
H. influenza 
Brady et al. 2008, 
Mohamed and 
Huang 2007 
Endotracheal 
tubes 
P. aeruginosa 
A. baumannii 
Gil-Perotin et al. 
2012 
Endocarditis Staphylococci 
S. pneumoniae 
Agarwal, Singh 
and Jain 2010 
Peripheral 
vascular 
catheters 
CoNS 
S. aureus 
Zhang et al. 2016 
Chronic 
sinusitis 
S. aureus 
P. aeruginosa 
H. influenza 
S. pneumoniae 
M. catarrhalis 
Tikhomirova and 
Kidd 2013, 
Tajudeen, Schwartz 
and Palmer 2016 
Intra uterine 
devices (IUDs) 
CoNS 
G. vaginalis 
Klebsiella spp. 
Staphylococci 
Abdel-Hafeez et al. 
2014 
Dental caries S. mutans 
A. naeslundii 
Huang, Li and 
Gregory 2011, 
Marsh 2006 
Contact lenses P. aeruginosa 
Achromobacter 
Stenotrophomonas 
Delftia 
Wiley et al. 2012, 
Robertson et al. 
2011 
Periodontitis P. gingivalis 
A. 
actinomycetemcomitans 
F. nucleatum 
Teles et al. 2013 Tissue fillers S. epidermidis 
P. acnes 
Christensen et al. 
2013 
Vaginosis G. vaginalis Patterson et al. 
2010 
Breast 
implants 
S. aureus 
S. epidermidis 
P. acnes 
Chessa et al. 2016, 
Rieger et al. 2013 
Kidney or 
bladder stones 
P. mirabilis Schaffer and 
Pearson 2015 
Urological 
prosthetics 
S. epidermidis Faller and Kohler 
2017 
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Several bacterial species are involved in biofilm-associated infections that 
can be caused by single- or multi-species biofilms (Martin et al. 2015). The 
source of infection involves commensal species, such as staphylococci and 
Propionibacterium acnes as well as environmental pathogens, such as P. 
aeruginosa (Joo and Otto 2012). The major pathogens involved in biofilm-
associated infections include both gram-positive, such as S. aureus and S. 
epidermidis, and gram-negative species, including P. aeruginosa and E. coli. 
Staphylococci are the most frequent cause of nosocomial infections, especially 
those associated with the use of catheters, orthopaedic materials, and 
implants, such as prosthesis and breast implants (Gomes, Teixeira and 
Oliveira 2014). The PIA produced by staphylococci has been shown to 
promote staphylococcal biofilm formation on foreign body materials (Olson 
et al. 2006). S. aureus is regarded as the most virulent representative, which 
infects both hospitalized patients and healthy immunocompromised 
individuals. In addition to the medical device-related infections, S. aureus is 
typically involved in osteomyelitis, endocarditis, chronic otitis media and 
sinusitis as well as in wound infections. Coagulase-negative staphylococci 
(CoNS), such as S. epidermidis, in turn, are the leading cause of medical device-
related infections (Vuong et al. 2003, Wu et al. 2015). Together, S. aureus and 
CoNS account for 50% of the prosthesis-related infections (Song et al. 2013). 
Of these infections, those occurring within the three first months after the 
surgery are typically caused by S. aureus. By contrast, delayed infections 
occurring postoperatively, are usually caused by CoNS. Late infections (24 
months after the surgery), in turn, are typically caused by S. aureus (Gbejuade, 
Lovering and Webb 2015). Moreover, S. aureus and CoNS are responsible for 
75% of osteomyelitis cases (Brady et al. 2008), and further staphylococcal 
biofilms along with streptococci and enterococci account for over 80% of 
infective endocarditis cases (Elgharably et al. 2016).  
P. aeruginosa is implicated in a variety of chronic biofilm infections, 
including cystic fibrosis, wound infections, sinusitis, otitis media, UTIs and 
keratitis. This bacterial species is the main causative bacteria of cystic fibrosis. 
Moreover, it is most frequently associated with the chronic pulmonary 
infections, such as pneumonia, particularly in cystic fibrosis patients (Høiby 
et al. 2010b, Moskowitz et al. 2004). In chronic wounds, P. aeruginosa is often 
found along with S. aureus, and particularly in the deeper layers of the 
wounds (Kirketerp-Møller et al. 2008). Typically, chronic wounds which are 
infected by P. aeruginosa are also deeper and larger in size than others 
(Gjødsbøl et al. 2006).  
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The leading cause of urinary tract infections (UTIs) is E. coli. These 
infections are also the most common cause of nosocomial infections, 
accounting for over 40% of all nosocomial infections (Jacobsen et al. 2008). Of 
these infections, 80% can be attributed to the use of urinary tract catheters 
(Sabir et al. 2017). In total, 10-20% of the hospitalized patients undergo 
catheterization, and among them, 10-50% develop a UTI. As a consequence, 
catheter-associated urinary tract infections (CAUTIs) cause one million 
additional hospital stays in the US every year (Hancock, Dahl and Klemm 
2010, Foxman 2002). 
2.1.4 Treatment of biofilm infections 
As mentioned earlier, the biofilm mode of growth contributes to the 
antimicrobial tolerance of bacteria. Thus, preventative strategies are 
advantageous to available treatment strategies. Further, bacteria in early 
stages of biofilm formation are still susceptible to antimicrobial therapy 
(Høiby et al. 2010a), and therefore, eradication of younger biofilms using 
conventional antibiotics may be possible. Unfortunately, early diagnosis of 
biofilm infections is usually difficult. No detection methods for the diagnosis 
of biofilm infections are currently available in the clinical settings (Percival et 
al. 2015). As a result, the majority of biofilm-associated infections involve 
mature biofilms, which are difficult or even impossible to eradicate. Two 
distinct approaches for the treatment of biofilm infections exist, preventative 
strategies aimed at prevention of biofilm formation, and treatment of 
established biofilm infections. 
2.1.4.1 Preventative approaches  
Various strategies have been utilized for prevention of biofilm formation 
on medical devices. These include modification of the surface, incorporation 
of antimicrobials into materials, and a combination of anti-adhesive and 
antimicrobial properties to inhibit the bacterial attachment to the surfaces 
(Arciola et al. 2012). For instance, antimicrobial-impregnated central venous 
catheters (CVCs) have been shown to effectively decrease the risk of infections 
(Raad et al. 2008). In clinical settings, CVCs impregnated with minocycline 
and rifampicin, marketed as the Cook Spectrum™ catheter, have been shown 
to be the most effective impregnations (Lai et al. 2016). Such catheters have 
been demonstrated to significantly decrease the number of catheter-related 
bloodstream infections (CRBSIs) compared to other catheters, such as 
chlorhexidine and silver-sulfadiazine-impregnated. Also, polyurethane 
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catheters (Hydrocath®) coated with a hydrophilic polymer, 
polyvinylpyrrolidone, and impregnated with benzalkonium chloride (BZK), 
a quaternary ammonium antimicrobial agent, prevent effectively risk of 
catheter-associated infections (Tebbs and Elliott 1994). On the contrary, 
marketed urinary tract catheters, such as silver alloy-coated latex catheters 
and nitrofurazone-coated silicon catheters, have only shown to postpone, not 
prevent, the emergence of CAUTIs (Francolini and Donelli 2010). However, 
the coated catheters have been demonstrated to be effective in short-term 
catheterization lasting less than 30 days. 
Antimicrobial lock therapy (ALT) is another important approach for 
preventing biofilm formation on CVCs. A combination of an antibiotic and 
heparin used for flushing or locking the line has shown to prevent catheter-
related (gram-positive mediated) infections by 50% (van de Wetering, van 
Woensel and Lawrie 2013). Antibiotic concentration used for ALT should be 
100- to 1000-fold higher than the planktonic minimum inhibitory 
concentration (MIC) (Høiby et al. 2015). The use of ALT is supported by the 
fact that antibiotics can help to minimize the dispersal of planktonic cells from 
the biofilms formed on the catheters (Wu et al. 2015). Additionally, 
conventional antibiotics can be employed prophylactically, which means that 
the antibiotic reaches the site of a potential infection before the causative 
microorganism (Høiby et al. 2015). 
2.1.4.2 Treatment using conventional antibiotics 
Selection of the right antibiotic is crucial when it comes to treatment of 
biofilm-associated infections. An antibiotic needs to be effective and well-
penetrating in order to obtain sufficient antibiotic concentration at the site of 
infection. Unfortunately, the MIC and the minimum bactericidal 
concentration (MBC), which are regarded as gold standards for determination 
of antimicrobial susceptibility of planktonic microorganisms, cannot be used 
to guide the antibiotic selection for biofilm-associated infections, as they 
hardly reflect the in vivo situation (Andrews 2001, Olson et al. 2002, 
Hengzhuang, Høiby and Ciofu 2014). Particularly, the MIC serves as an 
important reference for treatment of acute bacterial infections in vivo (Ceri et 
al. 1999). As biofilms are up to 1000-fold more tolerant to antibiotics than 
planktonic cells even in vitro, significantly higher concentrations than the MIC 
are needed for treatment of biofilm infections, and the recommended doses 
are only empirical (Høiby et al. 2015).  
In general, long-term antibiotic therapy with high doses is used for the 
tissue-related infections (Wu et al. 2015). Moreover, combination therapy is 
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typically recommended over monotherapy to obtain clinically effective 
concentrations (Raad et al. 2007). For the device-related infections, in turn, 
treatment involves removal of the infected device and surgical debridement 
in addition to aggressive antibiotic therapy (Percival et al. 2015). Similarly, 
treatment of wound infections also requires a combination of non-
antimicrobial and antimicrobial strategies. Typically, the mechanical 
debridement is combined with antimicrobial therapy involving two 
antibiotics from different mechanistic classes or a combination of an antibiotic 
and a local disinfectant (Høiby et al. 2015, Aslam 2008). 
For cystic fibrosis, aggressive antibiotic therapy is the most important 
treatment strategy. Since the eradication of infection is rarely possible, the 
treatment is aimed at preventing biofilm formation and, thus, the progression 
of the infection into a chronic state (Ciofu et al. 2012). A combination therapy 
involving nebulised tobramycin and colistin or inhaled colistin and orally 
administered ciprofloxacin has shown to be effective in postponing the 
emergence of chronic P. aeruginosa infections (Høiby 2011). For treatment of 
osteomyelitis, β-lactams, such penicillin G and oxacillin, which exhibit time-
dependent action, can be used against S. aureus (Archer et al. 2011). Moreover, 
polymeric-based materials, such as polymethylmethacrylate-gentamicin bone 
cement and beads (Septocal®), can be used for the treatment of bone and soft 
tissue infections (von Eiff et al. 2005).  Vancomycin is the most commonly used 
antibiotic for the treatment of S. aureus biofilm infections (Liu et al. 2011). 
However, rifampicin and daptomycin have been shown to be more effective 
than vancomycin against S. aureus biofilms (Smith et al. 2009, Kiedrowski and 
Horswill 2011). Typically, an effective combination therapy against S. aureus 
biofilm infections consists of vancomycin and rifampicin or daptomycin and 
rifampicin, as rifampicin has shown to enhance the efficacy of glycopeptide 
and lipopeptide antibiotics (Olson et al. 2010). Additionally, rifampicin 
remains the only antibiotic that is highly effective against staphylococcal 
biofilm infections. Importantly, when used in combination with other 
antibiotics, rifampicin represents the best current treatment along with 
surgical debridement for the treatment of prosthetic joint infections (Gómez 
et al. 2011). 
2.1.4.3 Treatment using enzyme-based products 
Poly-N-acetylglucosamine (PNAG), an exopolysaccharide produced by 
staphylococci, is an essential component of the biofilm matrix, which can be 
degraded by β-N-acetylglucosaminidase, Dispersin B, which is an enzyme 
produced by Aggregatibacter actinomycetemcomitans (Itoh et al. 2005). Dispersin 
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B has shown to disperse S. epidermidis and E. coli biofilms (Izano et al. 2008, 
Itoh et al. 2005). By contrast, dispersin B did not induce dispersal of S. aureus 
biofilms (Izano et al. 2008). Additionally, dispersin B has demonstrated 
synergistic activity with conventional antibiotics, leading to effective biofilm 
removal and killing the bacteria (Donelli et al. 2007, Darouiche et al. 2009). 
Dispersin B is commercially available as wound care gel and spray, and 
medical device coatings (Gawande, Leung and Madhyastha 2014, Miller et al. 
2014). Notably, these applications are not registered as drugs but as medical 
devices. However, they have been shown to enhance the clinical outcome of 
the chronic wound treatment (Wolcott and Rhoads 2008).  
Another enzyme-based marketed product is nebulized DNase, 
Pulmozyme (Dentice and Elkins 2016). The dornase alfa solution of 
recombinant human deoxyribonuclease I (rhDNase) is used as a mucolytic 
drug to promote improved clearance of secretions in the treatment of 
pulmonary disease in cystic fibrosis patients. 
2.2  Antimicrobial drug discovery  
In addition to the widespread presence of difficult-to-treat infections due 
to biofilm formation, the emergence of antimicrobial resistance (AMR) poses 
a significant threat to public health. Today, infectious diseases are the second 
leading cause of death worldwide and also, the third leading cause of death 
in developed countries (Fauci 2001). Drug-resistant bacteria cause poor 
clinical outcomes leading to increased health care costs and mortality. 
According to an estimate given by the CDC, more than two million antibiotic-
resistant infections, which are responsible for 23,000 deaths, occur in the US 
every year. Further, infectious diseases are associated with an economic 
burden of more than 120 billion dollars. In the European Union, antibiotic-
resistant infections lead to 25,000 annual deaths (Prestinaci, Pezzotti and 
Pantosti 2015). Both gram-positive, particularly methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium 
(VRE) and drug-resistant Streptococcus pneumoniae, and gram-negative 
bacteria, namely multidrug-resistant Acinetobacter baumannii (MRAB), 
carbapenem-resistant Enterobacteriaceae (CRE) and P. aeruginosa are resistant 
to multiple antibiotics and therefore of serious concern. For example, MRSA 
alone causes annually more deaths than HIV/AIDS, Parkinson’s disease, 
emphysema, and homicide combined (Ventola 2015, Pendleton, Gorman and 
Gilmore 2013). 
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Despite this, interests in antimicrobial drug discovery by pharmaceutical 
companies have declined. Antimicrobial drug discovery is considered as an 
economically unattractive investment (Projan 2003, Kresse, Belsey and Rovini 
2007). Typically, antimicrobials, especially antibiotics, are used for short-term 
therapy, in contrast to the drugs intended for the treatment of chronic 
diseases, such as cardiovascular diseases and diabetes. Further, novel, 
recently approved antibiotics are saved for future use. Additionally, 
regulatory requirements for marketing approval in the US and EU generate 
an extra challenge, as they have been uncertain and prone to change 
(Renwick, Brogan and Mossialos 2016). Thus, there has been a substantial 
decrease in the number of approved antibiotics. Altogether, eight antibiotics, 
ceftaroline, fidaxomicin, bedaquiline, dalbavancin, tedizolid, oritavancin, 
ceftolozane–tazobactam, and ceftazidime–avibactam, have been approved by 
the FDA (the US Food and Drug Administration) between 2010 and 2015. 
Only one of them, bedaquiline, is a first-in-class antibiotic with a novel 
mechanism of action, different from those of previously approved (Deak et al. 
2016). 
2.2.1 General aspects 
Drug discovery and development is a long and costly process (Figure 3). 
For a drug to be approved, it usually takes 12-15 years with a cost estimate of 
2.6 billion dollars (Hughes et al. 2011, Avorn 2015). A majority of drug 
candidates fail in clinical trials, or even before, either due to lack of efficacy or 
adverse effects (Mullard 2017, Kola and Landis 2004). In fact, only one out of 
5,000-10,000 lead compounds is approved and marketed as a drug (Balunas 
and Kinghorn 2005). Post-marketing safety monitoring conducted by the 
regulatory authorities after the approval can also lead to the withdrawn from 
the market in case of unfavourable benefit-risk assessment (BRAs) (Curtin 
and Schulz 2011). Antimicrobial drug discovery is not an exception with the 
estimated average of 8-12 years from discovery to market and, therefore, the 
discovery and development efforts need to be directed to meet the needs that 
will be present in 10 years (Thomson et al. 2004). 
 
Literature review 
 
18 
 
Figure 3. Schematic representation of the drug discovery process. This thesis project 
focused on the lead discovery stage, schematically depicted in Figure 5. 
Even though the time span between studies varies, some similarities can 
be seen.  The preclinical development before clinical trials takes 
approximately four years. The clinical trials including three phases typically 
take six years; one year for phase I involving 20–30 healthy volunteers in 
safety, tolerability, pharmacokinetic and dosage studies, 1.5 years for phase II 
involving 100–300 patient volunteers for investigation of the efficacy and side 
effects, and 3.5 years for phase III including 1000–5000 patient volunteers for 
monitoring the adverse effects related to long-term use. Finally, FDA review 
and approval takes one year as well as post-marketing monitoring (Martens 
and Demain 2017).  
2.2.1.1 Lead discovery process 
High-throughput screening (HTS), also referred to biomolecular screening, 
is an essential part of early drug discovery. It provides a practical way to 
identify hit compounds from large compound collections for further 
development. In the pharmaceutical industry, the standard antimicrobial 
bioassays, such as disk diffusion and broth or agar dilution, are not applicable 
in the antimicrobial drug discovery process in general, since assays need to be 
simple, rapid, inexpensive, and amenable for miniaturization (Swinney and 
Anthony 2011, Fallarero, Hanski and Vuorela 2014). The throughput of the 
standard methods is lower than that of HTS, and such methods are also more 
laborious and time-consuming compared to the HTS-based assays (von 
Nussbaum et al. 2006). Thus, the application of screening-compatible assays 
is essential for the efficient HTS of antimicrobials.   
During the biomolecular screening, multiple compounds are screened for 
identification of those displaying desired bioactivity utilizing phenotypic or 
target-based screening approach (Terstappen et al. 2007, De La Fuente et al. 
2006) (Figure 4). In phenotypic screening, compound libraries are typically 
screened using cell-based assays measuring effects on a particular 
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characteristic, such as cell proliferation in which several targets can be 
involved. In target-based screening, in turn, activity is measured against the 
pre-determined molecular targets, such as receptors or enzymes (Zheng, 
Thorne and McKew 2013).  
 
Figure 4. Phenotypic vs. target-based screening approach. 
Generally, target-based biochemical assays are more easily adaptable to 
HTS than cell-based phenotypic assays (Swinney 2013). However, target-
based screens and design have not been as productive tools as phenotypic 
screening in the antimicrobial area (Katsuno et al. 2015, Swinney and Anthony 
2011, Silver 2011), as phenotypic methods offer an unbiased mean to screen 
for targets in the complex biological systems. Moreover, phenotypic assays 
provide biologically relevant information, as the compounds are exposed to 
physiological conditions, such as cell membranes, cellular networks and 
different proteins. Thus, using the phenotypic approach, compounds 
affecting disease-related targets and signalling pathways can be identified 
(Schenone et al. 2013). However, the assays do not provide any information 
on the molecular mechanisms and targets of the compounds. Therefore, the 
subsequent identification of molecular targets responsible for the observed 
activity, termed target deconvolution, has to be performed (Hart 2005). 
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Several techniques are available for the target deconvolution. Proteomics and 
genomics-based approaches as well as high-throughput imaging platforms 
and computational methods can be applied to the identification of target 
proteins and pathways (Lee and Bogyo 2013).  
HTS of a compound library results in the identification of primary hits with 
the desired bioactivity. Subsequently, the primary hits are tested in secondary 
assays to confirm the activity and to eliminate the false positives. The 
confirmed hits are further assayed to characterize their potency and 
selectivity, as well as the physicochemical properties (Keseru and Makara 
2006). The ultimate goal of the hit-to-lead process (Figure 5) is to develop 
compounds with drug-like properties (Hughes et al. 2011). The lead 
development involving medicinal and combinatorial chemistry focuses on 
enhancing the pharmacokinetics and physicochemical properties aimed at 
improving the absorption, distribution, metabolism and excretion (ADME) 
and decreasing the toxicity. Notably, ADME properties are typically 
engineered at the expense of potency (Wassermann, Camargo and Auld 2014). 
The process is typically guided by Lipinski’s rule of five (RO5) (Lipinski et al. 
2001). According to the RO5, drug-like compounds shall fulfill the following 
criteria: molecular weight (MW) < 500 Da, octanol-water partition coefficient, 
log P ≤ 5, number of hydrogen bond donors ≤ 5, and number of hydrogen 
bond acceptors ≤ 10. The rule does not predict the pharmacological activity of 
the compounds, but describes the physicochemical properties that contribute 
to good oral absorption. This step is of great importance for selection of the 
best leads for pre-clinical studies, and also, for reduction of the attrition rates 
in pre-clinical and clinical studies (Hughes et al. 2011, Manly et al. 2008, 
Bleicher et al. 2003). 
 
 
 
Figure 5. Schematic illustration of the lead discovery process during the early drug 
discovery process. 
Even though the RO5 has had a beneficial impact on drug discovery in 
general, it is not ideal for antimicrobial lead discovery, as antimicrobials (e.g. 
antibiotics, disinfectants and antifungals) do not follow the rule (Lipinski et 
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al. 2001, Lewis 2013). Thus, when discovering effective antimicrobial leads 
that benefit from the active transport into the target cells or tissues, and can 
penetrate into the bacterial membranes, the RO5 should not be strictly applied 
in the lead development (Macarron 2006). 
2.2.1.2 Compound libraries 
Compound libraries fall into two categories, natural or naturally-inspired 
and synthetic compound collections (Hong 2011). Synthetic libraries, which 
obey the RO5, represent the majority of compound collections, currently 
available (Serrano, Kombrink and Meesters 2015). 
Natural products (NPs) differ from synthetic compounds in molecular 
properties. For example, NPs include more chiral centres and aromatic rings, 
and increased steric complexity, when compared to compounds obtained by 
synthesis. Moreover, NPs tend to contain more oxygen atoms than synthetic 
and semi-synthetic compounds, whereas synthetic compounds bear more 
nitrogen, sulphur and halogen atoms (Feher and Schmidt 2003, Koehn and 
Carter 2005). Additionally, natural compound libraries deviate from those 
designed according to the RO5, for example in terms of higher molecular 
mass, log P, and greater number of hydrogen bond donors and acceptors 
(Lipinski et al. 2001, Ortholand and Ganesan 2004). NP libraries can be 
composed of extracts (10-100 components) and partially purified fractions of 
microbial or plant origin (5-10 components) as well as of pure compounds 
(Shen 2015). Notably, NP libraries typically provide higher hit rates than 
synthetic libraries since natural scaffolds are evolutionarily optimized, 
complex drug-like compounds, which have evolved for optimal interactions 
with macromolecules in various biological systems. Moreover, many human 
protein targets include structural domains similar to the macromolecules (Li 
and Vederas 2009, Newman and Cragg 2016). 
Combinatorial chemistry allows fast synthesis of a large number of 
synthetic compounds with drug-like properties (Kaiser et al. 2008). However, 
such collections typically display limited structural and chemical diversity as 
well as occupy a different chemical space when compared to NPs, leading to 
lower hit rates (Payne et al. 2007). To overcome this, diversity-oriented 
synthesis (DOS) can be utilized (Cordier et al. 2008). The diversity-oriented 
approach focuses on the creation of libraries including structurally complex 
compounds aimed at identifying simultaneously therapeutic protein targets 
and their regulators (Kaiser et al. 2008). The DOS libraries include biologically 
and chemically diverse compounds with optimal physicochemical properties. 
Generally, such libraries have a greater likelihood to produce hits and 
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potential leads, when phenotypic screening is utilized (Wassermann et al. 
2014, Schreiber 2000). In contrast to DOS, target-oriented synthesis (TOS) 
generates smaller, focused libraries around specific scaffolds or chemotypes 
obtained either from biological screens or by virtual screening (Schreiber 
2000). As focused libraries include several analogues of previously identified 
leads, they have a higher likelihood of being active towards the pre-
determined target resulting in higher hit rates. However, the activity of such 
compounds is typically similar to that of the parent compound, and further, 
the TOS libraries occupy very narrow chemical space (Stockwell 2004, Kaiser 
et al. 2008). 
2.2.1.3 Statistical analysis 
To distinguish between active and inactive compounds, a threshold or a 
hit limit needs to be set. This can be either supported by statistical analysis or 
empirically set to obtain a reasonable number of hits for secondary screens 
(Walters and Namchuk 2003). Since bioactivity of the compounds in screening 
campaigns typically follows the normal distribution, the hit limit can be 
theoretically defined as standard deviations from the mean value of the 
compound collection signals. This way, the hit limit is set as 3 x SD (Zhang, 
Chung and Oldenburg 1999). High activity cutoffs lead to the identification of 
a few potent compounds for further optimization, and also, the diversity and 
chemical space occupied by the hits can be more limited. On the one hand, 
low activity cutoffs increase the diversity of the leads but, on the other hand, 
impede the further optimization of the leads (Zhu et al. 2013). Moreover, it is 
generally recognized that lower threshold for hits increases the number of 
false positive and false negative hits (Malo et al. 2006).  
Additionally, the statistical analysis offers the means to monitor screening 
quality. To ensure that the screening campaigns provide valuable and 
consistent data, statistical parameters, such as signal window coefficient (Z’ 
factor), signal-to-background (S/B) ratio (Zhang et al. 1999), signal-to-noise 
(S/N) ratio (Bollini et al. 2002), and coefficient of variation of the assay (CVA) 
are defined (Iversen et al. 2006). The assay quality is typically determined 
using Z’ both in the industry and academia (Inglese et al. 2007, Iversen et al. 
2006). In turn, S/B ratio alone is regarded as an insufficient parameter to 
evaluate screening quality as it does not take into account the variability of 
the signals. By contrast, S/N ratio alone provides a good assessment of both 
signal window and variability of the signal. However, S/B and S/N ratios are 
typically used in conjunction with Z’ (Zhang et al. 1999). 
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2.2.2 Drug discovery from natural products 
Natural products have been the leading source of inspiration in drug 
discovery and development (Newman and Cragg 2016). About 50% of 
marketed drugs are NPs or NP-derived, with approximately one-third of the 
world top-selling drugs being NPs or their synthetic derivatives (Kingston 
2011, Newman and Cragg 2012). Further, NPs, particularly from soil 
organisms, have provided the majority of lead structures for marketed anti-
infectives (von Nussbaum et al. 2006, Silver 2011). This can be explained by 
the fact that neither NPs nor antimicrobials follow the RO5 and, thus, their 
physicochemical properties resemble each other (Payne et al. 2007). In fact, all 
but four classes of antibiotics are NPs or their derivatives (Wright 2012). 
Altogether 112 antibacterial small molecule drugs were approved between 
1981 and 2014. Of these, NPs and NP-derivatives account for 73% (Newman 
and Cragg 2016). Similarly, most of the new antibiotics in late-stage 
development originate from NPs (Fernandes and Martens 2017). 
Even though NPs have provided significant value for drug discovery, 
pharmaceutical companies have declined NP drug discovery, since it has been 
considered laborious and challenging. Traditional drug discovery approaches 
involving fermentation broths and extracts of microorganisms are time-
consuming (Silver 2011). Also, when screening is conducted using crude or 
roughly fractioned extracts of NPs, additional steps, such as bioactivity-guided 
microfractionation, are required for the isolation and identification of the active 
component (Dandapani et al. 2012). Further, if the identified component is 
novel, a complete structural elucidation needs to be carried out. However, since 
NPs are usually complex in structure, identification of a pharmacophore and 
elucidation of structure-activity relationship (SAR) may be problematic 
(Ortholand and Ganesan 2004). Typically, the active component of an extract is 
a minor component and, therefore, inadequate for the further optimization and 
progression to the preclinical development (Balunas and Kinghorn 2005).  
Moreover, NP libraries, which consist of extracts and mixtures, are not 
compatible with current HTS platforms (Harvey 2008, Dandapani et al. 2012). 
In particular, the use of the target-based screening approach has prompted 
many pharmaceutical companies to use synthetic compound libraries instead 
of NP extract libraries (Koehn and Carter 2005). However, during the past 
decade, isolation and separation techniques, as well as structure elucidation 
methods, such as liquid chromatography–mass spectrometry (LC-MS) and 
nuclear magnetic resonance (NMR), have significantly improved, allowing 
higher throughput of natural extracts (Singh and Barrett 2006). Likewise, 
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antimicrobial screening strategies have improved and moved away from the 
early phenotypic assays, in which compounds were identified without any 
hypothesis of the possible mechanism of action, to high-throughput, whole-cell, 
target-based assays (Payne et al. 2007). Additionally, the use of pure, pre-
fractionated NP libraries has emerged as a means to screen NPs in HTS 
platforms (Dandapani et al. 2012).  
2.2.2.1 Natural compound collections explored in this thesis 
I Flavonoids (FL-500 Flavonoid derivatives, http://www.timtec.net/flavonoid-
derivatives.html) 
Flavonoids, plant and fungus secondary metabolites are among the most 
extensively studied classes of natural products with a polyphenolic nature, 
and widely reported for diverse antimicrobial activity, anti-biofilm activity 
included (Barbieri et al. 2017, Havsteen 2002, Friedman 2007, Ta and Arnason 
2015). The core structure of flavonoids is comprised of two benzene rings (A 
and B) linked through a heterocyclic pyran or pyrone (with a double bond) 
ring (c) in between (Figure 6). Altogether, more than 8000 flavonoids exist, 
and they are divided into 14 subclasses on the basis of oxidative status and 
substituents (Cushnie and Lamb 2011, Xie et al. 2015). Flavonoids exert anti-
biofilm activity in various ways, namely by preventing biofilm formation, 
dispersing existing biofilms and interfering with the signaling processes 
involved in biofilm formation (Borges et al. 2016).  
 
 
Figure 6. Chemical structure of the flavonoid core (A) and structural backbones of the 
major subclasses included in the library (B). 
The compound library explored in the present thesis, consists of both 
naturally occurring flavonoids and their derivatives from nine different 
classes, including representatives of flavanones, flavones, chalcones, 
flavonols, dihydroflavonols, flavans, anthocyanins, isoflavonoids and 
neoflavonoids. This library is an example of libraries combining features of 
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natural products by combinatorial chemistry to increase the likelihood of 
activity (Baker et al. 2007). 
II Amino acid derivatives of (+)-dehydroabietic acid (DHA) 
The resin acid (+)-dehydroabietic acid (DHA) (Figure 7) is present in 
conifers, where it serves as a defensive compound against herbivores and 
microbial pathogens (González et al. 2010). Antimicrobial properties of resin 
acids and other naturally occurring diterpenoids have been widely studied 
(González 2015, Leandro et al. 2014, Sipponen and Laitinen 2011) and a few 
studies have also focused on their anti-biofilm properties (Fallarero et al. 2013, 
Kuźma et al. 2007, Ali et al. 2012). The previous identification of DHA as a 
potent inhibitor of S. aureus biofilms (Fallarero et al. 2013) prompted into 
synthesis and discovery of DHA-based anti-biofilm compounds. In this study, 
DHA was used as an inspirational core structure for TOS of 30 novel amino 
acid derivatives, since D-amino acids had been previously reported to induce 
biofilm dispersal (Hochbaum et al. 2011, Kolodkin-Gal et al. 2010). The design 
strategy focused on chemical modification of rings A and B in the diterpenoid 
core and, moreover, the synthesis was further supported by simultaneous 
bioactivity testing. 
 
Figure 7. Chemical structure of (+)-dehydroabietic acid (DHA). 
III Natural product derivatives (NDL-3000, http://www.timtec.net/ndl-3000-
natural-derivatives-library.html) 
Natural product derivatives are typically synthesized using the concept of 
DOS, which relies on synthesis of compounds resembling natural products, 
also called mimics, or compounds that are based on natural product scaffolds, 
such as derivatives and synthetic analogues (Dias, Urban and Roessner 2012, 
Shang and Tan 2005). In the present thesis, a compound library consisting of 
3040 compounds, covering several compound classes, such as alkaloids, natural 
phenols, nucleoside analogues, carbohydrates, purines, pyrimidines, 
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flavonoids, steroidal compounds and amino acids, was explored. The use of 
natural compounds as scaffolds for combinatorial chemistry enables generation 
of compounds with enhanced structural diversity and drug-like properties. 
2.2.3 Anti-biofilm drug discovery  
In addition to general challenges associated with antimicrobial drug 
discovery, anti-biofilm drug discovery is even more complicated due to the 
specific features of biofilms. This is further exemplified by the fact that no 
specific anti-biofilm agents have been approved by the regulatory authorities 
so far. To date, all the marketed antibiotics are developed against dividing 
planktonic cells (Fey 2010).  
2.2.3.1 Targets and mechanisms of anti-biofilm agents  
Three main strategies for the biofilm control have been proposed: 
prevention of biofilm formation, interference with biofilm maturation and 
disruption of pre-formed biofilms (Gupta et al. 2016) (Figure 8).  
 
Figure 8. Strategies to control bacterial biofilms. Examples of both bactericidal and 
non-bactericidal approaches are shown in the boxes. Those marked in bold are included 
in this thesis. 
Literature review 
 
27 
 
Most likely, a combination of these strategies will be the most effective 
solution. Many anti-biofilm compounds are non-bactericidal that restore 
bacteria to the planktonic mode of growth, in which cells are more susceptible 
to antibiotics and host immune clearance. Furthermore, bactericidal 
approaches aimed at killing the bacteria can be utilized in biofilm control 
(Bjarnsholt et al. 2013b).  
The use of QSIs in biofilm control represents an attractive strategy, as QS 
is involved in several steps regulating biofilm formation, maturation and 
dispersal (Brackman and Coenye 2015). Moreover, QS is connected to the 
virulence and antibiotic susceptibility of bacteria (Brackman et al. 2011). 
Additionally, the QS systems provide several molecular targets, receptors 
involved in signal transduction, enzymes involved in signal molecule 
synthesis, and the signal itself (Reuter, Steinbach and Helms 2016). QSIs 
against both gram-negative and gram-positive bacteria have been identified 
both among natural and synthetic compounds, such as halogenated 
furanones (Hentzer et al. 2002), garlic (Smyth et al. 2010), patulin and 
penicillin acid (Rasmussen et al. 2005b), flavonoids, including quercetin and 
baicalein (Ouyang et al. 2016, Chen et al. 2016), indole derivatives (Biswas et 
al. 2015) and hammamelitannin analogues (Vermote et al. 2017). According to 
an estimate from 2008, QSIs could have reached the market in 2-7 years 
(Rogers, Carroll and Bruce 2012). However, even though several compounds 
have shown their QSI potential in vitro and in vivo, only a few clinical trials 
have been conducted or are being conducted (Reuter et al. 2016). 
D-amino acids, which are involved in several biological functions, have 
also demonstrated their potential in biofilm control (Cava et al. 2011).  Various 
D-amino acids have been shown to prevent biofilm formation and to induce 
biofilm dispersal in both gram-negative and gram-positive species 
(Brandenburg et al. 2013, Hochbaum et al. 2011, Kolodkin-Gal et al. 2010, Yu 
et al. 2016, Ramón-Peréz et al. 2014). Moreover, it has been demonstrated that 
amino acids enhance the efficacy of conventional antibiotics (Sanchez et al. 
2014) and biocides (Jia et al. 2017) against biofilms. Further, N-acetylcysteine, 
a mucolytic agent has been shown to interfere with biofilm formation of S. 
epidermidis (Pérez-Giraldo et al. 1997).  
Similarly, antimicrobial peptides (AMPs) have been shown to target 
several stages of biofilm development in several species. Additionally, AMPs 
have been reported to display synergistic activity with conventional 
antibiotics, and to modulate immune responses (Pletzer and Hancock 2016). 
AMPs target cell membranes and disrupt the cellular integrity leading to 
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translocation through the membranes (Fjell et al. 2011). One promising 
example of AMPs in biofilm control is human cathelicidin LL-37, which has 
been shown to inhibit P. aeruginosa biofilm formation at a concentration of 
1/16 x MIC and to eradicate pre-formed biofilms at micromolar concentrations 
in vitro. Moreover, it has been shown that LL-37 can interfere with QS of P. 
aeruginosa (Overhage et al. 2008). Currently, a few AMPs are in preclinical 
phase, and according to an estimate given by Czaplewski et al. (2016), they 
could be marketed as anti-biofilm agents at the earliest in 2027.   
Pilicides and curlicides, in turn, represent a non-bactericidal strategy to 
prevent biofilm formation. For instance, ring-fused 2-pyridones, such as 
FN075, have been shown to display anti-biofilm and anti-virulence activities 
by inhibiting the synthesis of curli and type 1 pili in uropathogenic E. coli both 
in vitro and in vivo (Cegelski et al. 2009, Guiton et al. 2012).   
Since metallic cations, such as Ca2+, Mg2+ and Fe2+, contribute to biofilm 
formation and maturation, metallo-chelators have been proposed as anti-
biofilm compounds (Abraham et al. 2012, Banin, Vasil and Greenberg 2005). 
Additionally, chelators have shown to potentiate the efficacy of conventional 
antibiotics in the killing of P. aeruginosa biofilms (Oglesby-Sherrouse et al. 
2014). A couple of chelators, such as deferasirox (DSX), have been approved 
by the FDA and are used against P. aeruginosa (Moreau-Marquis, O'Toole and 
Stanton 2009).    
The extracellular matrix components serve as an appealing target in biofilm 
control. For instance, matrix-degrading enzymes similar to dispersin B may act 
as effective dispersal inducers that enhance the efficacy of conventional 
antibiotics against biofilm-growing bacteria. Proteases, such as proteinase K 
and trypsin, which target matrix proteins, have shown to disperse S. aureus 
biofilms (Chaignon et al. 2007). Further, deoxyribonuclease, DNase has shown 
to induce dispersal of both gram-negative and gram-positive biofilms (Nijland, 
Hall and Burgess 2010). Additionally, diverse dispersal inducers have been 
identified. A fatty acid signalling molecule, cis-2-decenoic acid, produced by P. 
aeruginosa has been shown to induce biofilm dispersal of several species (Davies 
and Marques 2009), while nitric oxide has been demonstrated to promote 
dispersal of P. aeruginosa biofilms (Barraud et al. 2006).  
Notably, because the molecular targets vary between species, anti-biofilm 
strategies are not universal but species- or even strain-specific (Bjarnsholt et 
al. 2013b). Moreover, the effect of a particular compound may vary even 
between strains of the same bacterial species (Abraham et al. 2012). Most of 
the current investigational strategies rely on compounds, which interfere with 
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biofilm lifecycle without displaying bactericidal activity. Approaches that are 
not targeting the bacterial viability are generally considered less prone to the 
development of resistance (Sperandio 2007). Moreover, such compounds do 
not harm the natural bacterial flora (Joseph et al. 2016). However, when using 
non-bactericidal strategies, remaining planktonic cells can initiate biofilm 
formation again when the compound concentration has decreased enough. 
Thus, combinatory strategies of non-bactericidal, such as QSIs, and 
bactericidal approaches, such as conventional antibiotics or new 
investigational drugs, would be ideal for biofilm control to ensure long-term 
biofilm removal. By using adjuvants, the carriage of antibiotics can be 
reduced, and their efficacy can be enhanced. Thus, the risk of emergence of 
antibiotic resistance can also be minimized (Rogers et al. 2012).  
2.2.3.2 Models to study biofilms 
Several in vitro models have been developed for antimicrobial drug 
discovery against biofilm-growing bacteria. Models can be divided into two 
groups, closed (static) and open (dynamic) systems depending on the flow of 
nutrient media and waste products (Lebeaux et al. 2013) (Table 2, Figure 9).  
Table 2. Examples of in vitro models to study biofilms. 
 Closed system Open system 
 Microtiter 
well plate 
(MWP) 
Calgary 
Biofilm 
Device 
(CBD) 
Drip 
flow 
reactor 
(DFR) 
CDC reactor 
Type Batch Batch 
Plug 
flow 
reactor 
(PFR) 
Continuous 
flow stirred-
tank reactor 
(CSTR) 
Mixing Optional Optional Radial Perfect 
Fluid shear No/Low Gentle Low High 
Flow No No Yes, 
laminar 
Yes, turbulent 
Availability of 
a standardized 
protocol 
No 
Yes, 
ASTM 
E2799 
Yes, 
ASTM 
E2647 
Yes, 
ASTM E2562 
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MWP-based systems are closed (batch-reactor like) models, in which there 
is no flow in or out of the wells during the experiment. Consequently, the 
experimental conditions change because of nutrient depletion and 
accumulation of toxic products unless the growth media is regularly refreshed 
(Merritt, Kadouri and O'Toole 2005). However, MWP-based systems 
represent a versatile platform for anti-biofilm drug discovery, and they have 
been applied to anti-biofilm screening of natural compound libraries (Paytubi 
et al. 2017, Quave et al. 2008), susceptibility testing of antibiotics (Amorena et 
al. 1999, Ceri et al. 1999), efficacy testing of biocides (Pitts et al. 2003, Shakeri 
et al. 2007) and quantification of biofilm formation (O'Toole 2011). These 
devices are easy to handle and suitable for the use of multichannel pipettes, 
pipetting robots, and microplate readers (Duetz 2007). For HTS, the MWPs 
and the Calgary Biofilm Device (CBD) are the most frequently used 
(Bjarnsholt et al. 2013b). The CBD is a modified MWP, in which the 
polystyrene lid contains 96 pegs that can be fitted into the wells of a 96-MWP, 
allowing for biofilm formation on the pegs (Ali, Khambaty and Diachenko 
2006, Harrison et al. 2010). The MWP-based systems are fairly cheap, and for 
the assays, only small volumes of reagents and media are needed (Coenye and 
Nelis 2010). When conducting the MWP-assays under low shear conditions 
(on shakers), they enable mimicking of the flow conditions and biofilm 
formation in veins or on urinary tract catheters (Moreira 2013). Besides the 
MWP-based systems, agar plate-based models are representatives of static 
biofilm systems (Gabrilska and Rumbaugh 2015). They enable investigation 
of bacterial adhesion (Oja et al. 2014), anti-biofilm efficacy (Hiltunen et al. 
2016) and bacterial motility (Ha, Kuchma and O'Toole 2014). 
In contrast to closed systems, open systems provide a continuous supply 
of nutrient media and bypass of waste products (Coenye and Nelis 2010). 
Such models, including Drip flow reactor (DFR) and the Center for Disease 
Control (CDC) biofilm reactor, are designed for in-depth investigations. The 
goal of the open systems is to better simulate natural environments by 
providing shear conditions and nutrients. However, such models are typically 
less cost-efficient and more difficult to use than the MWP-based ones. 
Moreover, the throughput of these models is lower compared to the MWP-
based systems (Lebeaux et al. 2013).  
The DFR is defined as a plug flow reactor, in which cell density and 
nutrient concentration change along the length of the coupon in reactor 
channels (Goeres et al. 2009). The nutrient media is continuously supplied by 
dripping, thus creating low shear conditions inside the reactor. In such 
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growth conditions, biofilms also develop streamers that can be found both in 
environmental and medical systems (Franklin et al. 2015). Consequently, DFR 
promotes formation of heterogeneous biofilms mimicking those formed at the 
air-liquid interface in natural environments. The CDC biofilm reactor, in turn, 
allows biofilm formation under a constant flow of nutrient media under high 
shear conditions, which leads to the formation of thick biofilms on the 
coupons on swirling paddles. Such biofilms are often found in nature (Goeres 
et al. 2005).  
 
Figure 9. Experimental set-up of the biofilm models, MWP, CBD, DFR and CDC 
reactors from left to right. Supply of nutrients and mixing in each model is depicted 
in the top part of the figure, and images of the models are shown below. Picture of 
CDC reactor is courtesy of Darla Goeres. The upper part of the figure is adapted from 
Coenye and Nelis (2010). 
Coupons of various materials, such as silicone and ceramics, can be used 
in both reactors depending on the nature of the experiment and the conditions 
to be mimicked. Plug flow is typically found in pipes, tubing and catheters 
(Goeres et al. 2009). Moreover, the open systems can simulate infections that 
occur under the flow of fluids, such as in oral cavity (Adams et al. 2002), 
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wounds (Ammons, Ward and James 2011) and urinary tract (Curtin and 
Donlan 2006). Notably, as the hydrodynamic conditions and nutrient 
availability are crucial factors affecting the structure, density and thickness of 
the biofilms (Stoodley et al. 1998), the choice of the model system has been 
found to influence biofilm formation, and more importantly, antimicrobial 
susceptibility of the biofilms. Biofilms grown under turbulent flow in the CDC 
reactor have been found to be less susceptible than those grown under 
laminar flow in the DFR, and in the absence of flow in a static biofilm model 
(Buckingham-Meyer et al. 2007). 
2.2.3.3 Challenges of anti-biofilm drug discovery 
As previously mentioned, the antimicrobial research has traditionally 
focused on planktonic bacteria, and a wide variety of well-established in vitro 
methods exist (Balouiri, Sadiki and Ibnsouda 2016). Guidelines from the 
Clinical and Laboratory Standards Institute (CLSI) and the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) provide uniform 
testing procedures for antimicrobial susceptibility testing (AST) against 
planktonic bacteria. By contrast, no standardized methods have been approved 
by CLSI or EUCAST for evaluation of antimicrobial susceptibility of biofilms 
(Jacqueline and Caillon 2014). However, experimental standards for one anti-
biofilm screening assay applicable for susceptibility testing are available 
(ASTM E2799), as set by the American Society for Testing of Materials (Harrison 
et al. 2010). Altogether, five standards for biofilms exist (ASTM E2196, ASTM 
E2647, ASTM E2562, ASTM E2799, and ASTM E2871), and they all are suitable 
as such only for P. aeruginosa (Malone et al. 2017). 
Discrepancies between biofilm studies are frequently observed since the 
outcome is dependent on the experimental conditions, such as culture media, 
inoculum concentration and incubation conditions (Crémet et al. 2013, 
Stepanović et al. 2007). For the same reason, results from the in vitro studies 
may not correspond to the results obtained from in vivo studies (Barsoumian 
et al. 2015). Moreover, standardization is of great importance from the 
perspective of the regulatory authorities (Parker et al. 2014). Repeatability and 
reproducibility are essential attributes when considering the claims of anti-
biofilm efficacy.  
Similarly, conventional susceptibility breakpoints, including the MIC and 
the MBC, which are used to define the antimicrobial susceptibility of 
planktonic microorganisms (Andrews 2001, Olson et al. 2002) are not 
applicable for biofilms. To that end, the CBD was designed to assess the 
minimum biofilm inhibitory concentration (MBIC) (Moskowitz et al. 2004). 
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Furthermore, the CBD can be used for determination of the minimum biofilm 
eradication concentration (MBEC), which is defined as the lowest 
concentration of an antimicrobial agent required to eradicate existing biofilms 
(Olson et al. 2002). However, so far, results obtained using this device have 
not shown a breakthrough in the clinical settings (Waters and Ratjen 2015). 
This can be explained by the fact that biofilms formed on the pegs of the CBD 
reflect only partially the in vivo biofilms (Bjarnsholt et al. 2013a), as in vitro-
grown biofilms in general. However, the MBIC and the MBEC may facilitate 
the development of effective anti-biofilm drugs. 
To partially overcome the challenges associated with lack of 
standardization, the minimum information about a biofilm experiment 
(MIABiE) standards have been recently proposed (Lourenço et al. 2014). The 
MIABiE is not intended to provide specific standards for performing the 
biofilm experiments but to harmonize reporting of experimental data to 
enhance the reproducibility of experiments. Altogether, 15 modules that can 
impact the experimental outcome have been defined, for both data generation 
and characterization.  
From the translational perspective, the MWP-based models are the most 
limited systems, since the nutrients become quickly depleted restricting the 
biofilm development in respect of microenvironments and morphology 
(Roberts et al. 2015). Moreover, most MWPs are of polystyrene (Kumar, 
Wittmann and Heinzle 2004). However, such surfaces are not typically 
utilized in medicine, thus making them not particularly relevant in mimicking 
infection conditions. Overall, the major drawback of the in vitro models is the 
lack of host immune responses, which are typically present at the site of 
infection (Roberts et al. 2015). However, when using co-culture biofilm 
models, in vivo conditions can be better mimicked (Subbiahdoss et al. 2011). 
2.2.4 Anti-biofilm screening 
The HTS in early anti-biofilm drug discovery needs to be based on simple, 
accurate and reproducible assays, preferably suitable for automation, as in 
general (Inglese et al. 2007). Similarly, both phenotypic and target-based 
screening approaches can be utilized for the identification of hit compounds. 
In phenotypic screening, assays measuring the desired endpoints are first 
developed and optimized, followed by screening and hit identification. Later 
on, subsequent assays with the selected leads are required to gain mechanistic 
information of the leads, and to identify the molecular targets inducing the 
observed phenotypic effects. By contrast, in case of target-based screening 
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approach, molecular targets are first identified and validated, following the 
assay development and screening to identify hits and leads that act on the 
predefined targets of interest (Swinney and Anthony 2011).  
2.2.4.1 Phenotypic screening assays  
Phenotypic assays, which rely on diverse staining methods are widely 
applied to the HTS for biofilm inhibitors from large compound libraries 
(Junker and Clardy 2007, Panmanee et al. 2013, Opperman et al. 2009). These 
assays, in general, are inexpensive and easy to perform, allowing 
straightforward identification of biofilm inhibitors. However, the molecular 
basis of the observed effects is not known, as the phenotypic effects are non-
selective, measuring only the effects on selected characteristics according to 
the assay endpoint.  
Various MWP-based assays exist for quantification of the biofilm viability, 
total biomass and the matrix (Table 3). These features can be measured using 
a plate reader, for example, through fluorescence or absorbance at certain 
wavelengths. The MWP-based assays are broadly applicable, and when 
optimized for a particular species, they provide highly repeatable data 
(Peeters, Nelis and Coenye 2008, O'Toole 2011).  
Table 3. MWP-based assays used for biofilm quantification. 
Feature Assay Reference (ex) 
Biofilm viability Resazurin Sandberg et al. 2009 
 2,3-bis (2-methoxy-4-nitro-5-
sulfophenyl)-5-
[(phenylamino)carbonyl]-2H-
tetrazolium hydroxide (XTT) 
Pettit et al. 2005 
 Fluorescent fluorescein 
diacetate (FDA) 
Peeters et al. 2008 
 Adenosine triphosphate (ATP) Amorena et al. 1999 
Biofilm biomass Crystal violet Stepanovic et al. 2000, 
Sandberg et al. 2008 
 Congo Red staining Stiefel et al. 2016 
 Safranin Red Patterson et al. 2010 
Biofilm matrix Dimethylmethylene blue 
(DMMB) 
Toté et al. 2008 
 Wheat germ agglutinin 
(WGA) 
Skogman, Vuorela 
and Fallarero 2012 
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In the present thesis, resazurin and crystal violet staining assays were used 
to assess the anti-biofilm effects of compounds. Resazurin (7-hydroxy-3H-
phenoxazin-3-one-10-oxide), also termed Alamar blue, is a non-invasive 
redox indicator used to monitor cellular viability. Resazurin is reduced into 
resorufin, a fluorescent, pink dye as a result of metabolically active cells, 
indicating the fraction of viable cells (O'Brien et al. 2000, Van den Driessche et 
al. 2014). Upon this reduction, the pink colour is further reduced to colourless 
state due to atmospheric oxygen (Mariscal et al. 2009). Crystal violet 
(hexamethyl pararosaniline chloride) is a dye that indifferently stains the 
entire biofilm, including viable bacteria, dead cells and the matrix, whereas 
abiotic surfaces remain colourless (Stepanovic et al. 2000). After the staining, 
the adsorbed dye is eluted in a solvent, and the amount of the solubilized dye 
is directly proportional to biofilm biomass (Pantanella et al. 2013). As the 
assay does not distinguish between viable or dead cells or the matrix, it 
provides inaccurate information on the antimicrobial activity (Pitts et al. 
2003). By using a combination of two assays quantifying viability and total 
biomass, more comprehensive view of the antimicrobial activity of the 
compounds can be obtained, and moreover, it can be revealed whether the 
bacteria are removed or only killed (Stiefel et al. 2016, Toté et al. 2009). 
2.2.4.2 Target-based screening 
Contrary to phenotypic screening, target-based screening strategies focus 
on the identification of compounds that target a specific pathway or process 
essential for biofilm formation. Using this approach, specific biofilm 
inhibitors can be directly identified. QS represents a potential target, as it is 
involved in several stages of biofilm formation (Dickschat 2010), and an 
extensively used target in anti-biofilm screening (Hentzer et al. 2002, Jakobsen 
et al. 2012, Rasmussen et al. 2005a, Ding et al. 2011). In addition to the QS, 
specific amyloid proteins involved in biofilm formation, such as curli fibers of 
E. coli (Andersson and Chapman 2013, Cegelski et al. 2009), genes involved in 
nucleotide biosynthesis (Attila, Ueda and Wood 2009), and the intracellular c-
di-GMP (Antoniani et al. 2010, Sambanthamoorthy et al. 2014) have been 
employed as targets in target-based screening approach for biofilm inhibitors.  
In this thesis, QS system of C. violaceum was used as a target. In C. violaceum, 
production of the purple pigment violacein serves as a useful indicator of QS, 
whereas inhibition of QS leads to loss of the pigment (McClean et al. 1997). 
Compounds that inhibited violacein production were considered as QSIs.
Aims 
 
36 
 
3 Aims 
Given the widespread presence of biofilms, scaffolds that have co-evolved 
in nature offer a reasonable starting point for exploration of potent biofilm 
inhibitors. The overall goal of this doctoral project was to identify naturally-
inspired biofilm inhibitors from natural and naturally-derived compound 
libraries as alternatives to conventional antibiotics. A research strategy 
combining different screening approaches was utilized to identify bactericidal 
and non-bactericidal anti-biofilm leads, and further characterize their effects 
and mechanisms. In addition, a comparative efficacy study of conventional 
antibiotics was conducted in two different biofilm models. 
 
The thesis is composed of four studies: 
I. Flavonoids are one of the most widely studied classes of natural 
compounds with a variety of reported biological activities, including 
antimicrobial and anti-biofilm activities. The aim of this study was to 
develop a methodological workflow for screening of natural libraries 
with known antimicrobial properties, and apply it to the systematic 
exploration and characterization of biofilm inhibitors from a large 
flavonoids library.  
II. (+)-Dehydroabietic acid (DHA) has been previously identified as a 
potent anti-biofilm agent against S. aureus. The aim of this study was to 
screen a small compound library consisting of amino acid derivatives 
of DHA for anti-biofilm activity, and to investigate if linking of amino 
acids to DHA enhances the specific anti-biofilm activity. 
III. Quorum sensing (QS) controls biofilm formation of many bacteria. The 
aim of this study was to identify and characterize anti-biofilm scaffolds 
from a large compound library of natural product derivatives that act 
via inhibition of the QS without displaying bactericidal activity. 
 
IV. Several models have been developed to study biofilms and to evaluate 
antimicrobials against them. The aim of this investigation was to 
conduct efficacy studies of selected antibiotics from various 
mechanistic classes using microtiter well plates (MWP) and a drip flow 
reactor (DFR) to investigate the impact of the model system on the 
experimental outcome.
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4 Materials and methods 
4.1 Materials 
4.1.1 Bacteria and culturing conditions (studies I-IV) 
The culturing conditions for each bacterial strain used in the present thesis 
are summarized in Table 4. Working stocks of all bacterial strains were 
prepared from the glycerol stocks (20% w/v at -70 °C) onto agar plates and 
incubated overnight. Agar plates were stored at +4 °C for a period lasting not 
longer than four weeks. To reach the optimal culturing conditions, S. aureus, 
S. epidermidis, E. coli and P. aeruginosa were pre-cultured overnight. The actual 
cultures were prepared by diluting the pre-cultures 100-fold (E. coli, P. 
aeruginosa) and 1000-fold (S. aureus, S. epidermidis) in fresh media, and further 
incubating them (~4 h) to reach the exponential growth, until an optical 
density (OD595) of 0.3-0.5 corresponding to 108 colony forming units per 
milliliter (CFU/mL). Cultures of C. violaceum were incubated overnight to an 
OD595 of 0.7 corresponding to 109 CFU/mL. In all cases, bacterial concentration 
was confirmed by serially diluting and plating the cultures on agar for 
determination of CFU/mL as follows: 
ܥܨܷ/݉ܮ ൌ ሺே௨௠௕௘௥	௢௙	௖௢௟௢௡௬	௙௢௥௠௜௡௚	௨௡௜௧௦	௫	஽௜௟௨௧௜௢௡	௙௔௖௧௢௥ሻ௏௢௟௨௠௘	௢௙	௖௨௟௧௨௥௘	௣௟௔௧௘ௗ . 
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Table 4. Bacterial strains and growth conditions. TSA = tryptic soy agar, TSB = 
tryptic soy broth, LB = Luria-Bertani. 
Bacterium 
(strain) 
Agar Pre-
culture1 
Culture 
media2 
Growth 
conditions 
Study 
Staphylococcus 
aureus  
(ATCC 25923) 
TSA TSB TSB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
I, II, 
IV 
Staphylococcus 
aureus  
(Newman) 
TSA TSB TSB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
I, II, 
IV 
Staphylococcus 
epidermidis 
(ATCC 35984) 
TSA TSB TSB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
II, IV 
Staphylococcus 
epidermidis 
(ATCC 1228) 
TSA TSB TSB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
II 
Escherichia coli 
(XL1 blue) 
 
TSA TSB TSB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
II 
Escherichia coli 
(K-12) 
 
LB 
agar 
LB 
broth 
LB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
III 
Pseudomonas 
aeruginosa 
(PA01) 
LB LB LB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
III 
Pseudomonas 
aeruginosa 
(ATCC 15442) 
LB LB LB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
III 
Pseudomonas 
aeruginosa 
(ATCC 9027) 
LB LB LB Aerobic, 
+37 °C, shaking 
2201/2002 rpm 
III 
Chromobacterium 
violaceum  
(ATCC 31532) 
TSA - TSB Aerobic, 
+27 °C, shaking 
200 rpm 
III 
Chromobacterium 
violaceum 
(CV026) 
TSA - TSB Aerobic, 
+27 °C, shaking 
200 rpm 
III 
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4.1.2 Cell lines, media and incubation conditions (studies II and 
III) 
Mammalian cell lines were routinely cultured in 75 cm2 cell culture flasks 
at +37 °C in 5% CO2 in an air-ventilated humidified incubator to around 90% 
confluence. Harvesting was performed by trypsinization (0.25% (v/v)) for 
human lung cells or by physically scraping the adhered cells, for the RAW 
264.7 cells. Cell suspensions (60 000 cells/well, 200 L) were added into 96-
microtiter well plates and the plates were incubated for 24 h prior to exposure 
to compounds. The culturing conditions for the two cell lines used in the 
study are summarized in Table 5. 
Table 5. Cell lines and incubation conditions used in the study. 
Cell line Media Incubation 
conditions 
Study 
Human lung 
(HL) epithelial 
cells  
RPMI 1640 
supplemented with 
10% inactivated 
fetal bovine serum 
(FBS), 2 mM L-
glutamine and 
gentamycin 20 
µg/mL 
+37 °C,  
5% CO2 
 
II, III 
Mouse 
monocyte 
macrophage 
cells RAW 264.7 
Dulbecco’s 
modified eagle 
medium (DMEM) 
supplemented with 
10% FBS and 
gentamycin 20 
µg/mL. 
+37 °C,  
5% CO2 
 
III 
4.1.3  Compound libraries (studies I-III) 
Details on the sources of the compounds included in the present thesis are 
summarized in Table 6. Three compound libraries containing NPs, NP-
derivatives, semi-natural compounds and synthetic mimics were included in 
these studies. Libraries including 500 naturally occurring and natural 
derivatives of flavonoids (study I) and natural product derivatives (NDL-
3000) (study III) were purchased from TimTec®. The NDL-3000 library 
consisted of 3040 compounds from various classes, such as alkaloids, natural 
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phenols, nucleoside analogues, carbohydrates, purines, pyrimidines, 
flavonoids, steroidal compounds and natural amino acids. The in-house 
library of 31 amino acid derivatives of (+)-dehydroabietic acid (DHA) (study 
II) was synthesized by the research group of Professor Jari Yli-Kauhaluoma 
(University of Helsinki, Finland). A panel of conventional antibiotics (study 
IV), was obtained from several companies (see supplementary table S7 in 
publication IV for details). The compound libraries were prepared in dimethyl 
sulfoxide (DMSO, minimum 99.9%, Sigma-Aldrich, St. Louis, MO, US) at a 
concentration of 20 mM, and stored in MatrixTM library storage tubes at –20 
°C. For the screening assays, daughter plates with smaller aliquots of the 
compounds were prepared. Antibiotics were stored at –20 °C or +4 °C, and 
prepared either in Mueller-Hinton broth (MHB, Fluka Biochemika, Buchs, 
Switzerland) or DMSO depending on the solubility.  
Table 6. Compound libraries included in the study. 
Library Number of 
compounds 
Type Source Study 
Flavonoids 
(FL-500) 
500 commercial TimTec® 
(Newark, US) 
I 
Amino acid 
derivatives of 
(+)-DHA 
30 in-house 
Group of Prof. J. 
Yli-Kauhaluoma 
(University of 
Helsinki) 
II 
Natural 
product 
derivatives 
(NDL-3000) 
3040 commercial TimTec® 
(Newark, US) 
III 
Antibiotics 27 commercial 
Various suppliers 
(Supplementary 
table S7 in IV for 
details) 
IV 
4.1.4 Reference compounds (studies I-III) 
Penicillin G potassium salt (Fluka Biochemika, Buchs, Switzerland) was 
used as positive control in screening assays (studies I and II), while 
vancomycin hydrochloride hydrate (Sigma Aldrich, St. Louis, MO, USA) was 
included as additional control antibiotic (study II). (+)-Dehydroabietic acid 
was used as reference compound in study II. In study III, azithromycin 
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(Cayman chemicals, Ann Arbor, MI, US) was included as viability control and 
quercetin dihydrate (Carl Roth GmbH, Karlsruhe, Germany) as positive 
control in violacein and motility assays. Usnic acid (Sigma Aldrich, St. Louis, 
MO, USA) was used as control compound in cell viability assays (studies II 
and III).  
4.2 Methods 
4.2.1 Biofilm formation (studies I-IV) 
For biofilm formation, the exponentially grown bacteria were diluted to a 
starting concentration of ~106 CFU/mL, except for efficacy testing when 
biofilms were formed from diluted cultures of 107 CFU/mL (study IV). 
Information on the culture media used in biofilm formation is summarized in 
Table 7. The volume of the culture pipetted was 200 µL for 96-MWPs, 1.0 mL 
for 24-well plates, 1.5 mL for 12-well plates, and 5 mL for 6-well plates. The 
plates were routinely incubated at +37 °C, with shaking at 200 rpm for 18 h.  
Table 7. Culture media used for biofilm formation. 
Bacterium (strain) Culture media  
Staphylococcus aureus  
(ATCC 25923, Newman) 
TSB 
Staphylococcus epidermidis  
(ATCC 35984, ATCC 12228) 
TSB 
Escherichia coli (XL1 blue) 
 
TSB 
Escherichia coli (K-12) 
 LB 
Pseudomonas aeruginosa 
(PA01, ATCC 15442, ATCC 9027) 
LB 
Chromobacterium violaceum  
(ATCC 31532) 
LB supplemented with 0.1% w/v 
yeast extract (LBY) 
Chromobacterium violaceum  
(CV026) 
LBY 
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4.2.2 Exposure to compounds in microtiter well plates (MWP) 
4.2.2.1 Phenotypic screening (studies I and II) and antibiotic 
susceptibility testing (study IV) 
Bacteria were exposed to compounds in two modes, prior to and post 
biofilm formation. In pre-exposure mode of the assay, compounds and 
bacteria were simultaneously added into the wells, and incubated for 18 h 
(+37 °C, 200 rpm), while in post-exposure mode, biofilms were first formed 
for 18 h, and thereafter, exposed to compounds for 24 h (+37 °C, 200 rpm). At 
the end of the incubation periods, effects of the compounds were quantified. 
The workflow for the performed phenotypic screens is schematically 
summarized in Figure 10.  
Figure 10. Biofilm formation, exposure to compounds and quantification of S. aureus 
(studies I, II and IV), S. epidermidis (studies II and IV) and E. coli XL1 blue (study 
II) biofilms. 
4.2.2.2 Target-based screening (study III) and efficacy testing (study IV) 
Compounds and bacteria were simultaneously added into the wells and 
plates were incubated for 24 h (+27 °C, 200 rpm), or one hour (+37 °C, 200 rpm) 
in studies III and IV, respectively. In efficacy testing (study IV), bacterial 
suspensions were removed after one hour incubation with the tested 
antibiotics, fresh media was added and the plates were incubated for an 
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additional 24 h (+37 °C, 200 rpm). Effects of the compounds were determined 
at the end of the incubation periods. 
4.2.3 Bioassays 
An overview of the bioassays applied to the study is provided here, details 
of the experimental procedures can be found in the original publications 
(studies I-IV). 
4.2.3.1 Microtiter well plate (MWP)-based assays 
The MWP-based assays used in the study are summarized in Table 8.  
Table 8. Summary of the MWP-based assays. 
Assay Readout Endpoint Visual outcome 
Resazurin 
staining 
Fluorescence 
Viability, MBC, 
MBIC  
Crystal violet 
staining Absorbance Biomass, MBIC  
Turbidity assay 
(light scattering  
measurement) 
Absorbance 
Inhibition of 
bacterial 
growth, MIC 
 
Violacein 
reporter assay Absorbance 
Quorum 
Sensing (QS)  
ATP assay       
(CellTiter-
GloTM) 
Luminescence 
Viability, ATP 
efflux  
DiBAC4(3) Fluorescence 
Membrane 
depolarization  
4.2.3.1.1 Resazurin staining (studies I-IV) 
Briefly, 400 µM resazurin (sodium salt, Sigma-Aldrich, Steinheim, 
Germany) solution was prepared in phosphate buffered saline (PBS, Lonza, 
Vievers, Belgium) and added into the wells at a final concentration of 20 µM 
after removing the media (biofilms and cells). For planktonic bacteria, 
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resazurin was directly added to the wells. The plates were incubated in 
darkness, at room temperature (RT) for different time periods, optimized for 
every measured system:  5 min (for planktonic bacteria), 20-45 min (for biofilm 
bacteria, depending on the species) and 2 hours (at +37 °C for mammalian 
cells). Fluorescence was read at excitation and emission wavelengths of 560 
and 590 nm, respectively, using Varioskan Flash (Thermo Scientific, Vantaa, 
Finland) plate reader. The MBC was defined as the lowest concentration, 
which inhibited bacterial viability by 90% compared to untreated controls, 
and the MBIC was determined as the lowest concentration that inhibited 
biofilm formation by 90%, compared to untreated controls. 
4.2.3.1.2 Crystal violet staining (studies I, III and IV) 
Crystal violet staining was used to quantify the total biomass of biofilms. 
After removing the resazurin solution (studies I and IV) and the media (study 
III), the biofilms were stained with undiluted CV solution (2.3% (w/v) Sigma 
Aldrich, St. Louis, MO, USA) (studies I and IV) or diluted CV solution (0.23% 
(v/v, in MQ water) (study III) at RT for 5 min. After staining, the excess stain 
was washed off and the adsorbed dye was eluted in 96% ethanol. The amount 
of the solubilized dye, which is proportional to biofilm biomass, was 
measured spectrophotometrically at a wavelength of 595 nm after one hour, 
using Varioskan Flash multimode plate reader.   
4.2.3.1.3 Turbidity measurement (studies I and II) 
Bacterial light scattering (optical density) readings were used to determine 
the MIC against planktonic bacteria. For that purpose, at the end of overnight 
incubation, planktonic suspensions were transferred from the wells to sterile 
96-MWPs. The lowest compound concentration required to inhibit the visible 
growth of suspended bacteria was recorded, and the scattered light was 
measured at 620 nm using Varioskan Flash multimode plate reader. 
4.2.3.1.4 Violacein reporter assay (study III) 
Violacein production was assayed for identification of QSIs in C. violaceum 
ATCC 31532 and CV026 strains. The culture of C. violaceum CV026 was 
supplemented with N-(β-ketocaproyl)-L-Homoserine lactone (3-O-C6-(L)-
HSL, Cayman chemicals, Ann Arbor, MI, USA) to specifically induce 
violacein production. After 24 hours incubation with compounds, violacein 
was extracted by centrifugation and mixing in ethanol and the absorbance 
was read at 595 nm using Varioskan Flash multimode plate reader.  
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4.2.3.1.5 ATP quantification assay (studies II and III) 
Adenosine triphosphate (ATP) is widely used as an indicator of 
metabolically active cells (Weyermann, Lochmann and Zimmer 2005, Fan and 
Wood 2007).  The bioluminescent detection of ATP utilizes luciferase, an 
enzyme that catalyzes the formation of light from ATP and luciferin, and the 
luminescent signal is proportional to ATP concentration. CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega, Madison, WI, USA) was used to 
detect ATP efflux from the S. aureus ATCC 25923 biofilm cells (study II) and 
to study cytotoxicity (study III). At the end of the exposure period to 
compounds, suspensions were filtered (0.22 µm pore size) and 10-fold diluted 
in PBS. Equal volumes of filtrates and CellTiter-Glo® reagent were added into 
a MWP (study II). In study III, following the incubation period, the media was 
removed from the plates, and sterile PBS and CellTiter-Glo® reagent, in equal 
volumes, were added into the wells. The plates were shaken for 2 min and 
incubated at RT for 10 min, and the luminescent signal was measured at 560 
nm using Varioskan Flash multimode plate reader.  
4.2.3.1.6 DiBAC4(3) bis-(1,3-dibutylbarbituric acid)trimethine oxonol assay (study 
II) 
The membrane-potential-sensitive probe, DiBAC4(3) (InvitrogenTM, Thermo 
Fisher Scientific CA, US) was prepared in PBS (5 µM) and used to monitor 
membrane depolarization of S. aureus ATCC 25923 biofilms.  At the end of 
overnight incubation, the media was discarded and the biofilms were pre-
incubated with the probe for 30 min. After pre-incubation, the biofilms were 
incubated with compounds prepared in DiBAC4(3) solution at RT for 1 h. After 
1 h, the biofilms were washed twice with PBS and fluorescence was measured 
at excitation and emission wavelengths of 485 and 535 nm, respectively, using 
Varioskan Flash multimode plate reader. 
4.2.3.2 Agar plate-based assays 
4.2.3.2.1 Viable plate counts (studies I-IV) 
After the incubation periods, the biofilms were scraped off the substrates 
in the culture medium, disaggregated by sonication or by 
sonicating/vortexing, and the resulting suspensions were serially diluted and 
plated on agar plates (studies I, II and IV). In the case of planktonic bacteria, 
suspensions were removed by pipetting and homogenized by sonication, and 
serially diluted suspensions were plated on agar (studies I and III). Colony 
forming units (CFUs) were counted after overnight incubation, and the log10 
density (LD) of viable cells per volume (studies I-III) or surface area (study 
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IV) was determined. Efficacy of the compounds was assessed by a logarithmic 
reduction (LR) assay (Pitts et al. 2003), in which LR was calculated from the 
difference in LD of untreated controls and treated bacteria (studies I, II and 
IV). 
4.2.3.2.2 Motility assay (study III) 
QS-regulated swimming and swarming motility of P. aeruginosa PA01 was 
determined on 0.3% (w/v) agar plates (Figure 11). Test compounds were pre-
mixed with the agar and the solidified plates were point inoculated with P. 
aeruginosa (108 CFU/mL) and incubated at +37 °C for 18 h. The diameters of the 
swarming and swimming zones of the untreated and treated bacteria were 
measured after incubation. 
Figure 11. Schematic illustration of the motility assays. 
4.2.3.2.3 Drip flow reactor (DFR) assay (study IV)  
Diluted bacterial cultures (107 CFU/mL) were pre-mixed with antibiotics 
and added at a final volume of 15 mL to three of the reactor channels, while 
15 mL of bacterial culture was added to the control (fourth) channel. Biofilms 
in the presence or absence of antibiotics were formed on glass coupons placed 
in the channels by operating the reactor in batch phase (no flow) in a level 
position at +37 °C ± 2 °C for 1 h. After this batch phase, the reactor was drained 
and operated in continuous flow mode (flow rate 0.82 mL/min) at an angle of 
10° for 24 h. At the end of this period, coupons were removed from the reactor 
channels and rinsed with sterile water. The biofilms were dislodged and 
disaggregated by sonication and vortexing, and the efficacy of antibiotics was 
quantified by performing viable plate counts, as described in 4.2.3.2.1.   
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4.2.4 Imaging of biofilms (studies II, III and IV) 
4.2.4.1 Fluorescence microscopy (study II) 
Biofilms were formed on coverslips placed on the bottom of 24-well plates, 
as described in 4.2.1. Planktonic suspension was removed and the biofilms 
were exposed to compounds for 1 h. At the end of the exposure period, the 
solutions were discarded, and bacterial biofilms were stained with 
LIVE/DEAD® BacLight™ stain (InvitrogenTM, Thermo Fisher Scientific CA, 
US) for 15 min and imaged using an Inverted EVOS FL Epifluorescence 
Imaging System (InvitrogenTM, Thermo Fisher Scientific CA, US) with a 40x 
coverslip-corrected objective. 
4.2.4.2 Light microscopy (study III) 
Biofilms were formed on coverslips placed on the bottom of 6-well plates, 
as described in 4.2.1, but only for 2 h. Thereafter, planktonic suspensions were 
removed, and compounds and fresh media were added to the wells and the 
plates were incubated for 22 h. At the end of the incubation period, coverslips 
were rinsed, air-dried and stained with 0.23% (v/v) crystal violet solution for 
5 min. Imaging was carried out using EVOS® XL Imaging System 
(InvitrogenTM, Thermo Fisher Scientific CA, US) at a magnification of 40x. 
4.2.4.3 Confocal laser scanning microscopy (CLSM) (study IV)  
For CLSM imaging, biofilms were formed in 12-well plates and DFR for 1 
h. In MWP, planktonic suspensions were removed and fresh media was 
added into the wells followed by incubation for 24 h (+37 °C, 200 rpm). In 
DFR, biofilms were formed as described for control biofilms in 4.2.3.3. At the 
end of 25 h, the biofilms were stained with LIVE/DEAD® BacLight™ stain 
(InvitrogenTM, Thermo Fisher Scientific CA and imaging performed using an 
upright Leica SP5 Confocal Scanning Laser Microscope using the 488 and 
561 nm laser excitation lines. 
4.2.5 Data analysis (studies I-IV) 
Assay performance in screening assays was monitored by calculating Z’ 
factor, S/N and S/B (studies I-III). In the primary screening, all the compounds 
were tested in single wells (studies I and III), or in technical triplicates (study 
II), while during the follow-up studies, compounds were tested at least in 
three replicates and standard deviations (SDs) were calculated. For the half-
maximal inhibitory concentrations (IC50), 95% confidence intervals were 
calculated using GraphPad Prism software (version 5.0). In efficacy testing 
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(study IV), assay performance was evaluated in terms of coefficient of 
variation (CV) and repeatability standard deviation based on untreated 
control biofilms. Antibiotics were tested in duplicates, in at least three 
biological replicates (in MWPs) or five biological replicates (in DFR). SDs were 
calculated for each treatment. Statistical significance was determined using 
unpaired t-test with Welch’s correction in studies III and IV, and p-values < 
0.05 were considered as statistically significant. 
Statistical parameters were calculated according to the following 
equations: 
a) Signal window coefficient: 
ܼ′	 ൌ 	1 െ	൤3 ∗ ܵܦ௠௔௫ 	൅ 	3 ∗ ܵܦ௠௜௡|ܺ௠௔௫ െ ܺ௠௜௡| ൨ 
 
b) Signal-to-noise (S/N): 
ܵ
ܰ 	ൌ 	
ܺ௠௔௫ െ ܺ௠௜௡
ටܵܦ௠௔௫									ଶ ൅ ܵܦ௠௜௡								ଶ
 
 
c) Signal-to-background (S/B): 
ܵ
ܤ ൌ
ܺ௠௔௫
ܺ௠௜௡  
 
d) Coefficient of variation (CV): 
ܥܸ ൌ 	100% ∗ ൤ܵܦതܺ ൨ 
 
in which SDmin and Xmin correspond to the SD and mean value of the minimal 
signal, respectively, while SDmax and Xmax refer to the SD and the mean of the 
maximal signal, respectively.
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5 Results and discussion 
5.1  Statistical analysis of the assay performance 
(studies I-IV) 
Assay quality is an important aspect of the data analysis. To verify that the 
screening assays employed in the study performed well, and provided 
reliable and consistent data, assay performance was monitored by calculating 
statistical parameters: Z’ factor, S/B and S/N ratios (studies I-III), as originally 
described in Zhang et al. (1999) and Bollini et al. (2002). In general, Z’ is 
regarded as the preferred measure of assay performance for screening assays, 
and it shall be between 0.5 and 1 for an assay to be considered excellent 
(Zhang et al. 1999, Iversen et al. 2006). However, cell-based assays with Z’ 
values over 0.3-0.4 (Merten 2010, Iversen et al. 2006) are considered 
acceptable. The S/B ratio should be higher than 2, whereas for the S/N ratio, 
although no defined threshold value exists (Fallarero et al. 2014), higher S/N 
values indicate better assay performance (Zhang et al. 1999). 
In study IV, assay performance was evaluated in terms of repeatability by 
calculating the repeatability SDs and the CV as in Pitts et al. (2001). Low 
values for these parameters indicate high assay repeatability.  
5.1.1 Phenotypic screening (studies I and II) 
Effects of the compounds on biofilm viability and biomass were assayed 
using resazurin and crystal violet staining, respectively. Overall, for resazurin 
staining, all the calculated parameters were higher than those for crystal violet 
assay. The Z’ value was always higher than 0.4, which is a reliable indicator 
of well performing cell-based assays (Fallarero et al. 2014). By contrast, Z’ 
values in crystal violet assay varied considerably between plates. However, 
most of the Z’ values were over 0.3.  
As measured by means of Z’, the assay performance for resazurin staining 
in the primary screening is summarized in Figure 12.  
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Figure 12. Frequency distribution of Z’ values for the viability (resazurin) assay 
performed in two exposure modes, prior to (A) and post (B) biofilm formation against 
S. aureus ATCC 25923 and S. aureus Newman during the primary screening of 
flavonoids and DHA-derivatives libraries. Z’ is calculated based on the maximal and 
minimum signals of a plate. 
In terms of Z’, the assay performance during the primary screening was 
good to excellent (Zhang et al. 1999). Moreover, the calculated mean Z’ of 0.64 
± 0.08, indicated a large separation band between the maximum and 
minimum signals demonstrating high quality of the screening. The calculated 
S/B and S/N ratios of 19.8 ± 4.5 and 9.1 ± 3.0, respectively, also demonstrated 
a wide window between the controls, and were also considered highly 
acceptable. Noteworthy, the S/B and S/N ratios were higher than 2.8 and 3.2, 
respectively, for crystal violet staining. In view of the higher throughput and 
better reproducibility of resazurin assay, only data obtained on this assay 
were used as basis for the identification of anti-biofilm hits. In addition, only 
resazurin staining assay was applied to primary screening in study II. 
5.1.2 Target-based screening (study III) 
A comparative analysis of the Z’ values (Figure 13) calculated for violacein 
reporter and resazurin staining assays revealed that both screening assays 
performed well. The vast majority of the Z’ values were ≥ 0.5, and the lowest 
Z’ values, 0.46 and 0.48 obtained on three assay plates, were very close to 0.5 
and over 0.4, indicating the high signal robustness.  
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Figure 13. Correlation plot of Z’ values obtained for the violacein and viability assays 
during the primary screening in study III to discover QSIs without bactericidal 
effects. In total, 76 plates were screened. Panel A refers to C. violaceum ATCC 31532 
strain and panel B corresponds to C. violaceum CV026. 
The calculated mean Z’ values for violacein extraction and resazurin assays 
performed on C. violaceum ATCC 31532 were 0.68 ± 0.09 and 0.63 ± 0.07, 
respectively. For C. violaceum CV026, the corresponding values were 0.67 ± 0.1 
and 0.65 ± 0.09. The S/B and S/N ratios are summarized in Table 9.  All the 
calculated parameters proved that the assays performed well. 
Table 9. Statistical parameters calculated based on the primary screening. 
5.1.3 Efficacy testing (study IV) 
A comparative efficacy study of conventional antibiotics was performed in 
two distinct biofilm models, MWP and DFR. For both models, the 
repeatability SDs calculated based on the untreated control biofilms were low, 
0.17 and 0.41 for MWP (n = 27) and DFR (n = 11), respectively, indicating high 
assay repeatability (Pitts et al. 2001). A repeatability SD of zero would indicate 
a complete (ideal) repeatability, while a large repeatability SD demonstrates 
that the outcome is not repeatable. Further, the calculated CVs were low, 2% 
Parameter 
Violacein extraction Resazurin staining 
ATCC 31532 CV026 ATCC 31532 CV026 
S/N 12.0 ± 5.3 11.5 ± 6.8 8.7 ± 2.1 9.4 ± 3.2 
S/B 6.8 ± 2.1 7.8 ± 2.6 8.3 ± 2.2 7.5 ± 2.3 
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and 5% for MWP and DFR assays, respectively, reflecting low assay 
variability. A coefficient of variation of the signal <15% is considered 
acceptable (Fallarero et al. 2014). Thus, the assay produced reproducible data.  
5.2 Screening for biofilm inhibitors (studies I-III) 
Given the fact that biofilms are the predominant lifestyle of bacteria, 
scaffolds that have coevolved in nature offer a reasonable starting point for 
identifying anti-biofilm compounds with various mechanisms of action. A 
total of 3571 compounds from libraries containing both naturally occurring 
and naturally-inspired synthetic compounds were included in three studies. 
Of these, 531 compounds were screened for anti-biofilm activity against S. 
aureus ATCC 25923 and S. aureus Newman in two modes (prior to and post 
biofilm formation), and anti-biofilm activity was quantified based on biofilm 
viability using resazurin staining assay (studies I and II) as well as biomass 
using crystal violet staining assay (study I). This strategy was aimed at the 
discovery of anti-biofilm compounds with bactericidal effects. The second 
discovery strategy applied in this thesis focused on identification of non-
bactericidal compounds targeting QS. To that end, 3040 compounds were 
screened against C. violaceum ATCC 31532 and CV026 for QSI activity and 
viability in parallel (study III). The workflow of screening processes and 
selection criteria applied to the exploration of biofilm inhibitors from 
compound libraries (studies I-III) is schematically shown in Figure 14.  
The calculated hit rates, as defined based on the number of primary hits 
compared to the number of compounds included in the primary screening, 
were 2%, 80% and 0.3% for studies I, II and III, respectively. Typically, the hit 
rate during the primary screening is lower than 1% (Coma, Herranz and 
Martin 2009, Posner, Xi and Mills 2009). The higher hit rate in study I can be 
explained by the fact that flavonoids are reported for diverse antimicrobial 
activity (Havsteen 2002, Cushnie and Lamb 2005) and thus, expected to 
display also anti-biofilm properties. Further, natural compound libraries are 
known for higher hit rates than synthetic libraries, especially, when it comes 
to antimicrobial screening (Bérdy 2012). Moreover, phenotypic screening is 
generally considered more efficient than target-based screening in 
antibacterial discovery (Katsuno et al. 2015). The extremely high hit rate in 
study II was a result of the nature of the compound library. As the library 
synthesis was inspired by the previous identification of DHA as a potent 
inhibitor of S. aureus biofilms (Fallarero et al. 2013), and the DHA moiety was 
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included in each of the compounds in the library, the library was focused and 
also smaller in size.  
 
Figure 14. Schematic presentation of the screening process and selection criteria 
applied to the identification of biofilm inhibitors. Red boxes refer to study I, and orange 
and green to studies II and III, respectively. 
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5.2.1 Screening results, classification of the compounds and lead 
selection (studies I-III) 
5.2.1.1 Flavonoids collection (study I) 
It has been shown that the experimental outcome of antimicrobial studies 
is strongly affected by the assay conditions and materials employed in the 
testing (Jenkins and Schuetz 2012). To gain a comparative and systematic view 
of the antimicrobial activity of flavonoids, and to minimize the sources of 
experimental variations, a compound library of 500 naturally occurring and 
synthetic flavonoids was screened against S. aureus under similar 
experimental conditions. 
Primary screening conducted at 400 µM resulted in identification of ten 
primary hits, termed as highly actives. The hit limit was empirically set at 85% 
inhibition compared to untreated control biofilms on both strains and in both 
exposure modes, as quantified using resazurin staining. This allowed 
obtaining a reasonable number of potent hits that could be handled in the 
secondary assays. Further, 47 compounds, which displayed inhibitory activity 
ranging between 40 and 85% were classified as moderately actives. Finally, a 
total of 443 compounds had inhibitory activity less than 40%, and they were 
classified as inactives. Complete results of the primary screening based on 
resazurin staining are presented in Supplementary table 1 in study I. Anti-
biofilm effects of the ten highly active compounds on biofilm viability, as 
measured using resazurin staining, are shown in Figure 15, and their 
structures are shown in Supplementary table 2 in study I. 
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Figure 15. Anti-biofilm effects of the highly active flavonoids against S. aureus ATCC 
25923 and S. aureus Newman, when added prior to (pre) or post biofilm formation. 
The hit limit was set at 85% inhibition compared to untreated control biofilms. 
A selection criterion combining activity and selectivity was utilized for 
identification of anti-biofilm leads. To that end, a secondary screen at 100 µM 
with the ten highly active compounds was first conducted against S. aureus 
ATCC 25923 in two exposure modes. The ATCC strain was selected since the 
resazurin assay utilized here has been optimized using that strain (Sandberg 
et al. 2009, Skogman et al. 2012). Among the ten highly active compounds, 
representatives from four distinct classes, namely isoflavones (1), flavans (3), 
chalcones (3) and flavanones (3) were present. Further, of these compounds, 
six were naturally occurring, while four were synthetic derivatives. 
Interestingly, none of these highly active compounds was previously reported 
for any anti-biofilm properties.  
Upon confirmation testing at 100 µM, four compounds preserved the high 
activity (≥ 85% inhibition). A literature search using PubChem Bioassay 
project database (http://www.ncbi.nlm.nih.gov/pcassay) and Antimicrobial 
Index database (http://antibiotics.toku-e.com/) was performed. This search 
led to identification of two synthetic flavan derivatives, 6-chloro-4-(6- chloro-
7-hydroxy-2,4,4-trimethylchroman-2-yl)benzene-1,3-diol (291) and 4-(6-
hydroxyspiro[1,2,3,3a,9apentahydrocyclopenta[1,2-b]chromane-9,1′-
cyclopentane]-3a-yl)benzene-1,3-diol (369) as leads. Structures of the lead 
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flavonoids are shown in Figure 16, and their anti-biofilm and antibacterial 
activity are discussed further in 5.3.1. 
 
Figure 16. Chemical structures of the identified lead flavonoids. 
5.2.1.2 Amino acid derivatives of (+)-dehydroabietic acid (DHA) (study 
II) 
Previously, DHA has been identified as the most potent anti-biofilm 
compound within the class of abietane-type diterpenoids (Fallarero et al. 
2013). Here, various amino acids (L-, D- and unusual amino acids) were linked 
to DHA, and the library of 30 hybrid compounds was screened for anti-
biofilm activity against S. aureus. Primary screening led to the identification 
of 24 primary hits. Following the retesting of these primary hits at 100 µM, 
compounds that inhibited biofilms by more than 50% were selected for further 
studies. Six compounds met this criterion, and anti-biofilm potencies (IC50) 
against S. aureus ATCC 25923 were determined. Four compounds (4e, 9a, 9b, 
11) displayed potencies that were higher than or similar to the parent 
compound DHA (Figure 17). More importantly, all these compounds were 
more active than DHA in the post-exposure mode of the assay. Results from 
the entire testing are summarized in Supplementary tables 1 and 2 in study II. 
The two most potent compounds (9b and 11) were selected as leads. 
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Figure 17. Anti-biofilm potencies of the most active amino acid derivatives of DHA 
measured in both exposure modes against S. aureus ATCC 25923. DHA was used as 
the reference compound and is coded as 1. Error bars represent the 95% confidence 
intervals. 
In general, successful hybrid compounds should exhibit better bioactivity 
than the fused parts separately (O'Connell et al. 2013). The D-tryptophan 
derivative (9b) and the -cyclohexyl-L-alanine derivative (11), (Figure 18), 
which were selected as leads, were found to display significantly higher anti-
biofilm activity than the reference compound DHA. Moreover, as compared 
to the anti-biofilm activities reported for D-amino acids (Hochbaum et al. 
2011, Kolodkin-Gal et al. 2010), these derivatives are also more potent anti-
biofilm compounds. Thus, linking of particular amino acids to DHA enhanced 
its specific anti-biofilm activity. The activity of these two leads (9b and 11) is 
further discussed in 5.3.1. 
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Figure 18. Structures of the identified lead compounds. 
5.2.1.3 Natural product derivatives (study III) 
Various naturally-derived compounds and their synthetic derivatives have 
been identified as QSIs (Nazzaro, Fratianni and Coppola 2013, Cady et al. 
2012, Persson et al. 2005, Sintim et al. 2010). Compounds, such as alkaloids, 
phenols and carbohydrates, are involved in many biological processes and 
thus, thought to be a rich source of novel bioactive scaffolds (Cragg and 
Newman 2013, Koehn and Carter 2005). Here, a compound library of 3040 NP 
derivatives was screened for QSI using two strains of C. violaceum (ATCC 
31532 and CV026) as reporter bacteria.  
The threshold during the primary screening was set at 90% inhibition 
compared to untreated controls by means of violacein production in both 
strains. Moreover, all the compounds displaying bactericidal activity (≥ 40% 
inhibition on viability) were excluded, since QS is not affecting the bacterial 
growth. Therefore, inhibition of violacein production induced by bactericidal 
compounds cannot be considered as true QSI (Rasmussen and Givskov 2006). 
Based upon the primary screening at 400 µM, nine highly active hits were 
identified. Further, 328 non-bactericidal compounds were deemed as 
moderately active with an inhibitory activity between 40 and 90%, and the 
rest of the compounds were classified as inactives (n = 2062). QSI activity of 
the highly active compounds in the primary screening is shown in Figure 19, 
and the entire results from the primary screening are presented in 
Supplementary table 2 in study III.  
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Figure 19. Screening for QSIs. Inhibition of violacein production in C. violaceum 
ATCC 31532 and CV026 by the highly active compounds. The hit limit was set at 
90% inhibition compared to the untreated controls. 
Primary screening led to the identification of nine, structurally diverse highly 
active compounds from five distinct compound classes. Structures of these 
compounds are shown in Figure 3 in study III. This group comprised flavonoids 
(5), one alkaloid (1), a nucleoside analogue (1), an organosulfur compound (1) 
and a lignan (1). Given the chemical and structural diversity of the hits, no 
obvious structure-activity relationship seems to exist. Altogether, seven of them 
have not been previously reported for QSI activity against C. violaceum. 
For the lead selection, secondary screens with the highly active compounds 
were performed at 40 µM against C. violaceum ATCC 31532. This strain was 
selected, as the violacein production in C. violaceum ATCC 31532 is not 
dependent on exogenous addition of AHLs, thus enabling identification of 
QSIs, which do not interfere with the signaling process by degrading the added 
AHLs (Skogman et al. 2016). In this screen, only one compound exceeded the 
threshold value (90%). Thus, the cut-off value was decreased to 80% to obtain 
several compounds for further studies. Finally, a literature search using 
PubChem Bioassay project database (http://www.ncbi.nlm.nih.gov/pcassay) 
was conducted. Following the literature search, two flavonoid derivatives of 
flavone class, 2-(2-chlorophenyl)-4-oxochromen-3-yl propanoate (2117) and 2-
(4-methoxyphenyl)-4-oxochromen-3-yl decanoate (2896) were chosen as leads. 
Structures of the leads are shown in Figure 20 and the lead compounds are 
discussed more in 5.3.2.  
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Figure 20. Chemical structures of the leads. 
5.3 Follow-up and mechanistic studies 
5.3.1 Anti-biofilm potencies and antibacterial effects of the 
leads (studies I and II) 
Anti-biofilm potencies (IC50 and IC90 values) against S. aureus ATCC 25923 
were estimated based on at least 12 concentration points ranging from 0.01 to 
400 µM (study I) and 0.001 to 400 µM (study II). The effects of the compounds 
were quantified using resazurin staining assay, and the potencies were 
calculated using a non-linear regression analysis. The MIC values 
corresponding to the concentrations that inhibited 90% of planktonic growth, 
and the MBC against planktonic bacteria were determined based on turbidity 
and using resazurin staining, respectively. Results are shown in Figure 21.  
 
 
Figure 21. Structures, anti-biofilm potencies (A) and antibacterial effects (B) of the 
leads determined against S. aureus ATCC 25923. Error bars on the left represent the 
95% confidence intervals. 
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All the identified leads compounds, 291 and 369 (study I), and 9b and 11 
(study II), were shown to inhibit biofilm viability in a concentration-
dependent manner, and the calculated potencies were at micromolar range. 
In the pre-exposure mode, the IC50 values ranged from 9.4 to 33.2 µM (11 < 
291 < 369 < 9b) and IC90 values were between 13 and 60 µM (291 < 11 < 369 < 
9b). Potency (IC50) values recorded in post-exposure mode ranged from 27.8 
to 86.2 µM (11 < 291 < 369 < 9b). Thus, concentrations of the leads required to 
eradicate the pre-formed biofilms were only approximately 3-fold higher than 
concentrations needed to prevent biofilm formation. Of note, neither 
penicillin G nor vancomycin, which were included as reference compounds 
in the studies, was equally effective in the eradication of pre-formed biofilms. 
At the highest test concentration (400 µM), an inhibition of 57% and 25% was 
registered for penicillin G and vancomycin, respectively. This finding 
demonstrates the superiority of the identified leads in comparison to 
conventional antibiotics when tested in vitro against biofilm-associated 
infections.  
In addition to anti-biofilm activity, all the leads displayed antibacterial 
activity against planktonic cells. Overall, the antibacterial activity of the 
compounds was consistent with anti-biofilm activities in pre-exposure mode 
of the assay. The MIC values ranging from 15 to 60 µM (11 < 291 < 369 < 9b) 
were very similar to IC50 values determined against biofilm bacteria. Further, 
the determined MBC values between 10 and 40 µM (11 < 291 < 369 < 9b) were 
within the same range as the measured IC90 values. Consequently, the anti-
biofilm activity of these compounds in the pre-exposure mode of the assay is 
most likely connected to their ability to kill planktonic cells before the surface 
attachment. In this way, biofilm formation is inhibited by reducing the 
number of bacteria involved in biofilm colonization. However, all the 
compounds were also active in the post-exposure mode of the assay, 
indicating that the compounds display anti-biofilm activity independent of 
the bactericidal activity. 
Among the leads, compounds 291 and 11 were characterized as the most 
potent anti-biofilm compounds, while 11 was the most effective against 
planktonic bacteria. In general, compounds that inhibit the growth of 
microorganisms at concentrations below 10 µg/mL are considered as 
interesting antimicrobials (Ríos and Recio 2005). Of the hits, compounds 11 
and 291 fulfilled this criterion with MIC values of 6.8 µg/mL and 7.4 µg/mL, 
respectively. Among plant-derived antimicrobials, the activity of these 
compounds can be considered as a high-level activity, since usually the 
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reported MIC values range between 100 µg/ml and 1000 µg/mL, and are 
orders of magnitude higher than of antibiotics derived from bacteria or fungi 
(Tegos et al. 2002). Furthermore, if the antibacterial activity of flavonoids is 
taken into consideration, compound 291 falls within the top ten most active 
flavonoids reported by Cushnie and Lamb (2011). 
5.3.2 Killing efficacy of the anti-biofilm and antibacterial leads 
(studies I and II) 
The Log Reduction (LR) is commonly used as a measure of the efficacy of 
antimicrobials, and the LR assay is considered as the gold standard when 
quantifying the efficacy of anti-biofilm compounds (Pitts et al. 2003). A LR 
higher than 2 (≥ 2-log10-unit reduction in the numbers of CFU/mL or CFU/cm2 
in comparison to the untreated controls) demonstrates a 99% reduction of 
bacterial burden, and further a LR of ≥ 3 is regarded as an indicator of a 
significant reduction of the number of bacteria resulting in the killing of 
99.99% of the bacterial population. Furthermore, the killing of 3 log10 units is 
considered as a bactericidal mechanism (Traczewski et al. 2009), and 
importantly, LR of 3 indicates high anti-biofilm efficacy. The LR was 
determined by performing viable plate counts on the pre-formed biofilms 
after 24 hours exposure to the lead compounds (in the post-exposure mode). 
In study I, the killing efficacy of the lead compounds was quantified both 
against planktonic and biofilm bacteria, as the leads were found to display 
both antibacterial and anti-biofilm activity (Table 10). Compound 291 
resulted in a similar LR against both phases at all the test concentrations, thus 
confirming its equal antibacterial and anti-biofilm activities. Such compounds 
acting on both bacterial states at similar concentrations serve as promising 
starting points for novel, viable anti-biofilm compounds. Compound 369, in 
turn, was found to be more effective against planktonic bacteria yielding a full 
log reduction (no countable colonies on agar after the incubation period) at 
the two highest test concentrations with lower efficacy against biofilm 
bacteria. Thus, compound 369 can be considered more as an antibacterial than 
an anti-biofilm compound. 
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Table 10. Killing efficacy of the lead flavonoids assessed against planktonic and 
biofilm bacteria of S. aureus ATCC 25923. 
Compound Concentration (µM) 
Log Reduction (LR) 
Planktonic 
phase 
Biofilm phase 
291 
20 0.1 0.6 
80 0.7 1.5 
200 3.5 3.5 
400 4.7 4.6 
369 
50 1.2 1.5 
100 4.1 3.9 
250 9.0 3.1 
400 9.0 3.9 
Pen G 400 4.0 1.0 
Further, to confirm the efficacy of the identified leads in biofilm removal, 
compounds 9b and 11 were tested at 400 µM (Figure 22). The decrease in CFU 
ranged between 2.3 and 6.2 log10 units. The low efficacy of penicillin in biofilm 
removal was clearly demonstrated.  
Figure 22. Log reduction (LR) values caused by the identified leads and the reference 
antibiotic when tested against 18 hours biofilms at 400 µM. SDs were ≤0.4 in all the 
cases and compounds 291 and 369 were tested only once. 
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Killing efficacy studies also confirmed that none of the lead compounds 
can be regarded as a specific anti-biofilm compound. However, as the switch 
between two bacterial lifestyles, single cells and biofilms, is dynamic, the 
multifunctionality of these leads is advantageous compared to conventional 
antibiotics targeting only the dividing, planktonic cells. Such compounds are 
desirable antimicrobial compounds, as they can act both on planktonic and 
biofilm bacteria.  
5.3.3 Mode of action (study II)  
Since the leads were identified using a phenotypic screening approach, 
additional assays were performed to shed light on the underlying targets of 
the observed phenotypic effects (also known as target deconvolution) 
(Terstappen et al. 2007). First, time-kill kinetics of the leads were studied. As 
the leads (at 100 µM) were found to be fast-acting, causing more than 50% 
inhibition of biofilm viability after an exposure of one hour, their effects on 
the bacterial membrane were investigated. These studies revealed that the 
leads target the bacterial membrane, leading to membrane polarization and 
ATP efflux from the inner core of the biofilms (Figure 23). These findings were 
also confirmed by fluorescence imaging of the biofilms stained with live/dead 
stains SYTO 9 and propidium iodide.  
Such mode of action resembles the activity of antimicrobial peptides 
(AMP) (Matsuzaki 2009). However, AMPs are larger in size and more 
susceptible to enzymatic proteolysis. In contrast, the compounds 9b and 11, 
bearing a D- and an unusual amino acid as a side chain, respectively, are more 
stable and less prone to enzymatic proteolysis.  
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Figure 23. Events taking place after one hour exposure to the leads 9b and 11 and 
reference antibiotics. *p < 0.05; ***p < 0.001 indicate statistically significant differences 
when compared to untreated biofilms. Fluorescence microscopy images of biofilms, from 
left, untreated biofilm (A), biofilms exposed to 9b (B) and 11 (C) and reference 
antibiotics, penicillin G (D) and vancomycin (E). Scale bars correspond to 100 µm. 
5.3.4 Anti-QS activity (study III) 
Virulence inhibition strategies have been considered as promising 
alternatives for traditional antimicrobials, especially in case of biofilms. In 
contrast to other anti-biofilm leads discussed above, the identified lead 
compounds 2117 and 2896 displayed anti-biofilm activity via inhibition of QS.  
The N-acyl-homoserine lactone (AHL)-based QS system of C. violaceum, 
which consists of LuxI/LuxR homologs CviI/CviR (Stauff and Bassler 2011), 
was utilized as the target in primary screening. Following the initial testing 
against C. violaceum, which included primary and secondary screens along 
with potency assessment, activity of the identified leads was investigated 
against other gram-negative bacteria, including P. aeruginosa. In P. aeruginosa, 
LuxI/LuxR homologs RhlI/RhlR and LasI/LasR coordinate swarming motility 
and transition from microcolonies to fully formed biofilms, respectively 
(Köhler et al. 2009, Davies et al. 1998).  
Results from the QSI studies for C. violaceum and P. aeruginosa PAO1 are 
summarized in Figure 24. The identified lead compounds were shown to 
affect several QS-mediated features involved in different stages of biofilm 
formation and bacterial virulence to varying degrees, but they were not 
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detrimental to bacterial growth. Even though the leads inhibited violacein 
production in C. violaceum at low micromolar concentrations with the IC50 
values of 9.6 and 13.9 µM for 2117 and 2896, respectively, their activity against 
P. aeruginosa was significantly lower even at the highest test concentration 
(400 µM). Such differences can be attributed to the species-specificity 
associated with QSIs over the system specificity (Jakobsen et al. 2012). 
 
Figure 24. Structures and potencies (IC50 values) of the leads determined against C. 
violaceum ATCC 31532 (A), and effects on biofilm maturation, swarming motility 
and viability of P. aeruginosa PAO1, as assayed at 400 µM (B). 
Effects of the leads on biofilm maturation and architecture were also 
visualized using light microscopy (Figure 25). The biofilm density was 
significantly higher in the untreated control biofilm. 
 
Figure 25. Light microscopy imaging of crystal violet stained P. aeruginosa PAO1 
biofilms. From left, untreated control (A), microcolonies exposed to the lead 
compounds 2117 (B) and 2896 (C). The measured OD595 values after crystal violet 
staining are shown in each image. Scale bars correspond to 100 µm. 
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5.3.5 Selectivity of the leads (studies I-IV) 
Even though ATCC strains are well characterized and preferred to be used 
in antimicrobial testing (Cos et al. 2006), two strains of S. aureus (ATCC 25923 
and Newman) were included in primary screening to avoid identification of 
strain specific-hits (studies I and II). Screening of the flavonoids library (study 
I) resulted in more strain-specific hits, while the activity of amino acid 
derivatives of DHA was generally similar against both strains (study II). Such 
characteristics have also previously been reported for flavonoids (Cushnie 
and Lamb 2011). For the same occasion, antibiotic susceptibility testing 
performed in study IV was conducted against two strains of S. aureus (ATCC 
25923 and Newman) and one strain of S. epidermidis (ATCC 35984). In study 
III, the use of the ATCC strain and the violacein-deficient mutant strain CV026 
in parallel, enabled distinction between real QSIs and quorum quenchers 
(QQs). The QSIs inhibited violacein production in both strains, while the QQs 
were active only against the mutant strain requiring the addition of 
exogenous AHLs to produce violacein. 
In study II, during the follow-up studies, the activity of the six most active 
compounds and the parent compound DHA was assessed against S. 
epidermidis ATCC 12228 and ATCC 35984 in addition to S. aureus ATCC 25923 
and Newman. Additionally, a gram-negative strain E. coli XL1 was included 
in the study to investigate, whether the identified hit compounds would 
display broad-spectrum activity (against both gram-positive and gram-
negative species). Generally, broad-spectrum antimicrobials are esteemed as 
powerful tools to treat infections caused by a wide range of bacteria (Lynch 
2012). No significant activity against the gram-negative representative was 
shown, indicating selective, narrow spectrum activity against gram-positive 
bacteria. However, all the compounds were active to varying degrees against 
other gram-positive strains when tested at the IC50 concentration determined 
against S. aureus ATCC 25923 in the pre-exposure mode of the assay, thus 
suggesting a broader anti-staphylococcal spectrum. Results for the lead 
compounds 9b and 11, as well as for penicillin G included as a control 
antibiotic, are shown in Table 11. 
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Table 11. Anti-biofilm activity of the DHA-derived leads against three other biofilm- 
forming strains measured at IC50 concentration determined against S. aureus ATCC 
25923. 
Strain Inhibition percentages of biofilm formation (%) 
9b 11 Pen G 
S. epidermidis  
ATCC 12228 
70.3 ± 5.6 42.3 ± 9.5 28.0 ± 2.3 
S. epidermidis  
ATCC 35984 
66.9 ± 0.9 48.8 ± 4.8 15.5 ± 15.0 
E. coli  
XL1 Blue 
8.7 ± 5.6 5.2 ± 11.3 9.6 ± 6.2 
Antimicrobials with a narrow activity spectrum are considered as less 
harmful with lesser effects on beneficial bacteria (Silver 2011). Moreover, use 
of narrow-spectrum antibiotics that target only a specific pathogen can 
diminish the emergence of antibiotic-induced resistance (Levy and Marshall 
2004).  
5.3.6 Cytotoxicity of the leads (studies II and III) 
An ideal anti-biofilm agent should be safe and effective as drugs in general. 
Typically, long-term treatment with antimicrobials at high doses is needed for 
treating biofilm infections (Beloin et al. 2014). Thus, anti-biofilm agents, as 
well as antibiotics in general, have an enhanced risk of toxicity due to high 
doses needed to achieve the desired efficacy (Lewis 2013). Furthermore, in 
contrast to many other therapeutic areas, in which lack of efficacy is the major 
cause of attrition, the clinical safety and toxicology are among the most critical 
factors for antimicrobials (von Nussbaum et al. 2006). Cytotoxicity testing on 
cell cultures predicts potential toxic effects in animals and humans (Riss and 
Moravec 2004, Mahto, Yoon and Rhee 2010). The identified lead compounds 
were tested against human lung (HL) epithelial cells (studies II and III) and 
mouse monocyte macrophage RAW 264.7 cells (study III) (Table 12). After 24 
h exposure to compounds, compound 9b was found to be cytotoxic (~80% 
inhibition of cell viability) at 100 µM, while compound 11 was shown to be 
slightly cytotoxic (~10% inhibition of cell viability) (study II). At the lower test 
concentrations, compound 9b was also non-cytotoxic (0-10% inhibition of cell 
viability). In study III, compound 2117 was cytotoxic against RAW 264.7 cells 
at the highest test concentration, whereas against HL-cells it demonstrated 
minor cytotoxicity. Compound 2896, in turn, did not exhibit any cytotoxic 
Results and discussion 
 
69 
 
effects even at the highest test concentration. In general, natural compounds 
are regarded as less toxic than synthetic compounds. 
Table 12. Cell viability measured using resazurin staining assay (study II) and based 
on ATP levels (study III). N.A. = not analyzed. 
Compound Concentration (µM) 
Percent of cell viability (%) 
HL RAW 264.7 
9b 1 95.7 ± 10.7 N.A. 
 50 93.0 ± 8.1 N.A. 
 100 23.0 ± 5.9 N.A. 
11 1 98.5 ± 1.3 N.A. 
 50 93.9 ± 6.4 N.A. 
 100 92.6 ± 6.7 N.A. 
2117 40 100.1 ± 0.8 101.1 ± 1.0 
 100 88.8 ± 4.9 1.2 ± 0.5 
2896 40 104.9 ± 3.7 104.0 ± 3.9 
 100 102.6 ± 0.8 103.6 ± 4.8 
5.4 Insights into biofilm models: MWP vs DFR (study 
IV) 
Several in vitro models have been developed for biofilm research. In this 
study, efficacy of selected conventional antibiotics for biofilm prevention in 
the MWP and the DFR, representatives of closed and open systems, 
respectively, was assessed. The experiments were conducted utilizing a 
similar experimental set up to investigate the impact of the biofilm model on 
the experimental outcome and biofilm formation. Even though conventional 
antibiotics developed to kill or inhibit the growth of exponentially growing 
bacteria are generally inefficient against biofilm bacteria, they serve as a 
potential strategy for biofilm prevention (Kohanski, Dwyer and Collins 2010). 
5.4.1 Selection process of antibiotics for efficacy testing 
Initially, a susceptibility testing involving a panel of 27 clinically used 
antibiotics from various mechanistic classes was performed. Planktonic 
bacteria were exposed to two-fold dilution series of antibiotics at 22 
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concentrations, ranging from 4.88x10-4 mg/L to 1024 mg/L, and the MBIC 
values were quantified. Moreover, effects of the antibiotics at the same 
concentration range against pre-formed biofilms were evaluated.  As 
expected, all the antibiotics were more effective in the pre-exposure mode of 
the assay. When assayed in the post-exposure mode of the assay, none of them 
was able to reduce biofilm viability by more than 60%. However, results from 
resazurin and crystal violet assays were fairly similar, indicating the 
bactericidal activity of the antibiotics against biofilm forming bacteria 
(Skogman et al. 2012). The entire results of the susceptibility testing are shown 
in Supplementary tables 1-4 in study III. Results of the ten most active 
antibiotics, when tested against S. aureus ATCC 25923, are summarized in 
Table 13. These antibiotics were selected further for the efficacy testing, first 
performed in the MWP.  
 
Table 13. MBIC values determined using resazurin and crystal violet staining, 
respectively, and the effects on pre-formed S. aureus ATCC 25923 biofilms using 
resazurin staining assay. N/A = not available. 
 MBIC Effects on pre-formed 
biofilms 
Antibiotic 
Viability Biomass Viability Inhibition-
% mg/L µM mg/L µM mg/L µM 
Penicillin 0.0156 0.04 N/A N/A ≥0.0625 0.18 ~60 
Clindamycin 0.0313 0.07 0.0313 0.07 ≥0.25 0.59 ~50 
Rifampicin 0.0313 0.04 0.0625 0.08 ≥0.0313 0.04 ~50 
Doxycycline 0.125 0.12 0.25 0.24 ≥4 3.90 ~60 
Tetracycline 0.25 0.52 0.125 0.26 ≥2 4.16 ~50 
Oxacillin 0.25 0.52 0.125 0.30 0.125 0.30 ~50 
Ampicillin 0.25 0.62 0.125 0.31 ≥0.5 1.24 ~60 
Dicloxacillin 0.5 0.98 0.5 0.98 ≥0.125 0.24 ~50 
Levofloxacin 0.5 1.38 0.5 1.38 ≥32 88.55 ~50 
Vancomycin 2 1.37 N/A N/A ≥8 5.38 ~50 
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5.4.2 Efficacy testing in MWP 
The efficacy of the selected antibiotics in biofilm prevention was quantified 
using LR assay in MWP. Antibiotics were tested at four concentrations, 0.1, 1, 
10 and 100 µM. The entire results are shown in Supplementary table 5 in III, 
and for the highest test concentration (100 µM) presented in Figure 26.  
Figure 26. LR of ten selected antibiotics when tested at 100 µM in MWP. Rif = 
rifampicin, Oxa = oxacillin, Amp = ampicillin, Dic = dicloxacillin, Levo = levofloxacin, 
Dox = doxycycline, Clin = clindamycin, Tet = tetracycline, Pen G = penicillin G, Van 
= vancomycin. 
In this testing, penicillin G resulted in a LR of 2.91 ± 0.22 when assayed at 
100 µM. In contrast, when killing efficacy was quantified against pre-formed 
biofilms in study I, penicillin G, used as the reference antibiotic, caused a LR 
of 1 at 400 µM upon an exposure of 24 h. These results demonstrate the 
antimicrobial tolerance associated with biofilms and notably, the fact that 
biofilm tolerance increases over time (Stewart 2015). Based upon the MWP 
testing, rifampicin, oxacillin and doxycycline were selected for DFR testing in 
order to include antibiotics with several targets and mechanisms of action. 
5.4.3 Comparative efficacy study in MWP and DFR 
In the DFR, rifampicin, oxacillin, and doxycycline were tested at 100 and 
1000 µM. Results of the efficacy testing performed at 100 µM in the MWP and 
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the DFR are included in Figure 27. Biofilms grown in the DFR, when operated 
in continuous flow mode constantly providing fresh nutrients, were 7 to 26 
times more tolerant to antibiotics than those grown in the absence of flow in 
the MWP, as quantified by means of Tolerance Factors (TF) (Stewart 2015). 
However, when the flow was eliminated from the DFR, the efficacies of the 
most active antibiotics rifampicin and doxycycline, when assayed at 100 µM, 
were almost similar to those measured in the MWP (Figure 27). Complete 
results from the efficacy testing are presented in Tables 1 and 4 in publication 
IV, and the TFs in Tables 2 and 5. 
 
Figure 27. LR measured for the three selected antibiotics at 100 µM in both models. 
Experiments in the DFR were performed with and without the flow. Rif = rifampicin, 
Oxa = oxacillin, Dox = doxycycline. 
Several factors were analyzed to understand the differences in LRs 
between models. For that purpose, surface-area-to-volume (SA/V) ratios, 
which reflect the biofilm area exposed to antibiotics, were calculated. Further, 
the mean LD of control biofilms grown in both models, as well as the 
concentration of the planktonic inoculum used for biofilm formation, were 
compared (Table 14).  
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Table 14. Comparison of the models. 
Model 
Surface-area-to-
volume (SA/V) 
ratio 
Control biofilm 
(log10 CFU/cm2) 
mean ± SD 
Planktonic 
inoculum 
(log10 CFU/mL) 
mean ± SD 
MWP 7.961 cm-1 8.07 ± 0.17 8.29 ± 0.21 
DFR 2.708 cm-1 7.60 ± 0.41 8.26 ± 0.25 
Differences in the LR between the models could neither be attributed to 
differences in surface-area-to-volume (SA/V) ratios nor to bacterial density. 
Thus, the only clear factor that affected the differences was the nutrient flow 
(Figure 27). Moreover, biofilm architecture varied between the models, as 
visualized with CLSM (Figure 28). Biofilms grown in the DFR (C-D) were 
more heterogeneously distributed than the MWP-grown biofilms (A-B). 
Moreover, the DFR-grown biofilms were composed of larger clusters of 
bacteria.  
 
 
 
Figure 28. CLSM images of S. aureus ATCC 25923 biofilms grown in the MWP (A-
B) and the DFR (C-D). Images are representatives taken from different positions of 
one well in a MWP and from different locations within one coupon in the 
DFR. Biofilms are stained with LIVE/DEAD BacLight kit. Scale bars correspond to 
30 µm. 
Both models produced consistent and reproducible data, as shown in 5.1.3. 
However, they both fail in the complete reproduction of in vivo conditions, 
especially those bacteria encounter during chronic infections. Thus, none of 
the models can be judged as better than the other; one is only more suitable 
than another for a particular research question.
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6 Conclusion and outlook 
Currently, the discovery of strategies to cure biofilm-related infections is 
one of the most challenging and complicated tasks in antimicrobial drug 
discovery. Obviously, there has not been much success yet. To date, the best 
way to eliminate biofilm infection is by preventing it, that is, by killing the 
bacteria when they are in the planktonic mode of growth or by inhibiting the 
initial attachment. All the marketed antibiotics are developed against 
dividing planktonic cells, and the vast majority of existing standardized 
methodologies and in vitro breakpoints are applicable only for planktonic 
bacteria. Biofilm models intended for in vitro research, though there are 
several options available, are inadequate in mimicking conditions that occur 
in chronic biofilm infections. Moreover, the biofilm research suffers from the 
lack of standardization.  
Conventional antibiotics alone are typically inefficient to overcome biofilm 
infections. Therefore, a combination of aggressive antibiotic therapy and 
surgery is often needed. An ideal anti-biofilm agent should preferentially 
affect the biofilm viability, biomass and the matrix. Thus, combinatory 
strategies involving both bactericidal and non-bactericidal approaches, i.e. 
QSIs or dispersal agents, would represent the optimal treatment strategy. The 
adjunctive compounds targeting bacterial virulence also help the host 
immune system to overcome infection.  
The results obtained during this thesis project demonstrated the potential 
of natural compounds as biofilm inhibitors. Several compounds with various 
mechanisms of action from distinct compound classes were identified. 
Phenotypic screening, in studies I and II, led to the identification of 
multifunctional leads, which displayed both antibacterial and anti-biofilm 
properties in contrast to conventional antibiotics. Such compounds can be 
considered as desirable anti-biofilm compounds because they can first kill the 
planktonic population, thus, reducing the number of bacteria involved in 
biofilm formation, and thereafter, affect the biofilm lifecycle in another way. 
The identified leads (two synthetic flavan derivatives as well as the D-
tryptophan and the β-cyclohexyl-L-alanine derivatives of DHA) inhibited 
biofilm formation and eradicated pre-formed biofilms at low micromolar 
concentrations. Additionally, two flavone derivatives were characterized as 
the non-bactericidal leads in study III, in which a large compound library of 
natural product derivatives was screened for QSI using a target-based 
screening approach. These flavone derivatives inhibited biofilm formation 
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and maturation by interfering with the QS-mediated processes, but they did 
not kill bacteria.  
In the future, these compounds could be further optimized towards more 
potent anti-biofilm compounds or adjunctive agents. Especially flavonoids, 
which have been reported to display synergistic activity with conventional 
antibiotics, call for future testing in combinatory studies. Moreover, the 
identified QSIs would show the best potential when used as adjunctive 
agents, as they do not kill the planktonic bacteria and in this way, do not 
provide long-term anti-biofilm effect alone. Furthermore, additional testing 
of the identified leads against more pathogenic and resistant strains would be 
of great relevance, as the antimicrobial resistance poses a significant threat to 
global health. In that context, compounds that display their activity via non-
bactericidal mechanisms could also help in minimizing the risk of resistance 
development. 
Several models have been introduced for in vitro biofilm studies aiming to 
ease translation from in vitro to in vivo results, especially during drug 
discovery approaches. Efficacy testing of conventional antibiotics in biofilm 
prevention conducted in study IV, revealed that the experimental outcome is 
strongly dependent on the choice of model. These findings are in line with 
previous studies showing that the presence of flow substantially impacts the 
biofilm formation, and importantly, antimicrobial susceptibility of biofilms. 
As biofilms grown under flow were significantly more tolerant to antibiotics, 
the results suggest that the identified biofilm leads need to be tested in distinct 
biofilm models to facilitate the selection of the best compounds for in vivo 
studies. Notably, most biofilms outside the laboratory form under conditions 
in which flow is present. However, the final application of an anti-biofilm 
agent is the determinant for the model selection.
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